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ABSTRACT 
Increasingly, lung cancer treatment depends on the molecular characteristics of the 
lung tumour and studying the mechanisms of potential lung cancer molecular 
markers is important in order to identify new, targeted treatment options. The cell 
surface protein, EpCAM is one potential therapeutic target. Traditionally considered 
an adhesion protein, recent studies in breast and colon cancer have shown that 
EpCAM also undergoes proteolytic cleavage. Its c-terminal tail is released, acting as 
nuclear signalling factor that may contribute to cancer progression.  
Lung Cancer is the leading cause of global cancer-related mortality, largely due to a 
tendency for late-stage diagnosis. Screening with CT scans suffers from high false 
positives and requires additional confirmatory diagnosis, using more invasive 
techniques. Less-invasive detection methods could potentially improve the ease of 
screening and detection, increasing the chances for early diagnosis. EpCAM is widely 
used as a target for isolating circulating tumour cells (CTCs) from the blood of cancer 
patients. This is problematic as EpCAM-positive CTCs only represent a sub-
population of total CTCs. This thesis evaluates the clinical utility of EpCAM-
independent CTCs detection for diagnosis, as well as the mechanisms of EpCAM 
cleavage, in the context of lung cancer. 
Two different EpCAM-independent CTC isolation systems were assessed. Both 
isolate CTCs from peripheral blood using a size- and deformability-exclusion strategy. 
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The Clearbridge system comprises a microfluidic chip with permeable traps and the 
ScreenCell system utilizes a permeable membrane subjected to a vacuum pressure 
gradient. A combination of primary, matched normal and tumour lung tissue and 
lung cancer cell lines were used to investigate EpCAM cleavage activity in lung 
cancer.  
The ScreenCell system was both easier to use and produced better results than the 
Clearbridge system. EpCAM cleavage experiments showed that while it does occur in 
lung cancer, it differed from previously reported EpCAM cleavage behaviour in 
breast and colon cancer cell lines. The most interesting difference was the discovery 
of N-terminal cleavage in lung cancer, which has not been described in published 
literature. 
While both CTC-isolation systems have the potential to be used as a diagnostic blood 
test for lung cancer, low sensitivity and specificity values prohibit their use in the 
clinical setting presently. The discovery of EpCAM cleavage in lung cancer, especially 
N-terminal cleavage, is particularly relevant in the context of treatment strategies 
targeting extracellular domains of EpCAM, and EpCAM cleavage mechanisms and 
their effect on lung cancer progression warrants further exploration. 
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TNF-a tumour necrosis factor-α 
TNM  tumour, node, metastasis 
 18 
1 INTRODUCTION 
1.1 Current paradigms in lung cancer 
1.1.1 Lung cancer statistics and the role of screening in early detection 
According to the most recent global cancer survey in 2012, lung cancer remains the 
leading cause of cancer-related mortality, responsible for 1.59 million deaths that 
year and accounting for close to 20% of all cancer-related deaths.1 It is the only 
cancer-related cause of death to feature in the list of top 10 causes of global 
mortality, coming in 6th behind ischaemic heart disease, stroke, chronic obstructive 
pulmonary disease and lower respiratory infections.2 The vast majority of all lung 
cancers are non-small cell lung cancers, accounting for approximately 85% of all 
cases.3 Across all stages of the disease, lung cancer also has a poor 5-year survival 
outcome of less than 15% and a 10-year survival rate of less than half of that.4 The 5-
year survival rate of lung cancer has only increased from 13% in the mid 1970s to 
15% in the mid 1990s. This increase is marginal, compared to the increase in breast 
cancer 5-year survival from 75% to 88% within the same reference periods.5 This is 
largely due to the fact that symptoms mostly present themselves in later stages of 
lung cancer, resulting in most diagnoses occurring in patients with advanced or 
metastatic lung cancer.4 In England and Wales, stage IV patients accounted for close 
to 50% of all diagnoses of lung cancer from 2006 to 2008.6 
One strategy for increasing survival involves screening for early detection of lung 
cancer; however the effectiveness of current proposed lung cancer screening 
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strategies remains controversial. Proposed lung cancer screens typically involve 
detection of early-stage tumours via imaging platforms, namely chest radiography 
and computed tomography (CT). The Prostate, Lung, Colorectal and Ovarian cancer 
screening trial (PLCO) showed no significant reduction in mortality in lung cancer 
with annual screening, using chest radiography, compared to no screening.7 Eight 
European CT screening trials are currently on-going. Five-year results of one of these, 
the Multi-centric Italian Lung Detection Trial (MILD), showed no significant reduction 
in mortality with annual or biennial low-dose CT screening compared to no 
screening.8 The US National Lung Cancer Screening Trial (NLST) found a 20% 
reduction in mortality, when employing three annual low-dose CT scans compared 
to the equivalent number of chest radiography scans, to screen a high-risk test 
population. High-risk participants were identified as smokers from 55 to 74 years of 
age with a 30 pack-year smoking history or former smokers within the same age 
range, who quit within 15 years before commencement of the trial. However, false 
positives occurred in 39% of screened participants, resulting in invasive and 
expensive follow-up procedures that ultimately did not detect cancer.9 While low-
dose CT screening is recommended for individuals that fall in the high-risk group in 
the US, in general, screening for lung cancer is not widely practiced globally, and 
there is no national screening programme in the UK.  
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1.1.2 Lung cancer staging, histological subtyping and conventional 
chemotherapeutic treatments 
After detecting anomalous growths in the lung via chest radiography or CT scans, 
histological confirmation of the tumour is carried out, in order to determine the 
malignancy, staging and subtype of the tumour. The collection of tumour histological 
samples is achieved using a variety of methods, depending on the size and location 
of the tumour. These range from minimally invasive techniques, including fibreoptic 
bronchoscopy with biopsy, transbronchial needle aspiration and bronchoalveolar 
lavage, to more invasive procedures, such as transthoracic needle aspiration and 
surgical biopsy. The treatment strategy is ultimately dependent on pathological 
staging and subtyping of the retrieved cytological or histological specimens. 
Tumours are staged according to the tumour, node, metastasis (TNM) system, 
continually developed and updated by the International Association for the Study of 
Lung Cancers (IASLC). Table 1-1 shows the 7th edition of the TNM classification 
system. Staging depends on the size of the tumour (T), involvement of lymph nodes 
(N) and the presence of metastases (M).10 Surgical removal of the tumour is the 
preferred treatment where possible, especially in resectable T1 and T2 tumours. 
Depending on the size and spread of the tumour, different types of surgical resection 
procedures are performed. The majority of the procedures performed in the UK are 
lobar resections (lobectomies), which have a lower mortality rate than removal of an 
entire lung (pneumonectomy). Sub-lobar wedge and segmental resections are 
performed where the size and spread of the tumour does not necessitate the 
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removal of a lobe, and sleeve resections are performed when a portion of the 
bronchus needs to be removed.6  
T3 tumours may or may not be resectable, and multimodal therapy involving 
chemotherapy or radiotherapy prior to surgical resection, is sometimes employed in 
some T3 N2 tumours. However, this is controversial, as the survival rates of pre-
operative multimodal therapy compared to radiotherapy or chemotherapy alone did 
not significantly improve in these studies. In unresectable stage I to III tumours, 
radiotherapy or chemotherapy is usually advised, and generally, in all stage I to III 
tumours, multimodal therapy (various combinations of surgery, radiotherapy and 
chemotherapy) is administered, based on assessment by thoracic oncologists and 
surgeons. 6  
Aside from staging, subtyping of tumours is important in deciding treatment 
strategies. Non-small cell lung cancer (NSCLC) is the most common type of lung 
cancer, accounting for 80% of all lung cancer cases.11 Within NSCLC, lung 
adenocarcinomas (ADCs) and squamous cell carcinomas (SqCCs) are the most 
common subtypes. Until the 1970s, SqCCs, which develop mainly in the central 
tracheal and bronchial airways, were the prevalent subtype. Since then, ADCs have 
surpassed SqCC to be the leading lung cancer subtype diagnosed globally. ADCs 
typically arise in the peripheral lung and this shift from SqCC to ADC prevalence has 
been attributed to the advent of filter-tipped cigarettes, which requires deeper 
inhalation to induce an equivalent impact, and which therefore involves exposure of 
the peripheral airways to cigarette smoke.12 A breakdown of the subtypes of lung 
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cancer patients diagnosed from 2006 to 2008 in England and Wales is presented in 
table 1-2. The global trend of higher incidence of ADC compared to SqCC does not 
seem to be present in these reported cases, but this is likely due to the large fraction 
of unclassified NSCLCs, indicated by NSCLC (NOS).  
Until relatively recently, the standard treatment for NSCLC was chemotherapy using 
third-generation platinum-based drug combinations, regardless of histological 
subtype.13 Chemotherapy drugs are cytotoxic agents that target hyperproliferative 
cells, including, but not limited to, cancer cells, via numerous mechanisms that 
generally act to impair cell division. Recent studies have found that treatment 
response and patient survival differed among the different types of 
chemotherapeutic drugs, depending on the histological subtype of the tumour. For 
example, pemetrexed, an anti-metabolite that impairs DNA synthesis, showed 
greater effectiveness in treating non-squamous tumours compared to squamous 
lung tumours. Pemetrexed treatment in ADC and large cell carcinoma patients 
correlated with significantly higher overall survival and progression-free survival 
compared to SqCC patients.14 Treatment options are more limited for SqCC 
compared to ADC and elderly patients are frequently undertreated due to concerns 
regarding the toxicity of the chemotherapy regimens available. The microtubule 
disruptor paclitaxel was traditionally employed in a solvent-based form (sb-
paclitaxel) to treat NSCLC. A newer, albumin-bound form (nab-paclitaxel) has been 
shown to correlate with significantly higher overall response rates, corresponding to 
the reduction in tumour size, and higher safety and tolerability in treating SqCC, 
compared to sb-paclitaxel.15 
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Table 1-1. TNM classification and staging, 7th edition 10 
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1.1.3 Targeted therapy in the treatment of NSCLC  
 
1.1.3.1 EGFR  
Increasingly, lung cancer subtypes are being further sub-categorised based on their 
molecular profiles, specifically the presence of mutations leading to abnormal 
expression of certain target oncogenes. While there is a multitude of mutated genes 
that contribute to oncogenesis and cancer progression, a sub-class of these genes 
drives cancer initiation and progression.16 Recent approaches in cancer therapy have 
aimed to target these driver mutations. The use of targeted therapies differs 
between ADCs and SqCCs, reflecting the differing incidences of various driver 
mutations in the two lung cancer sub-types. Figure 1-1 shows a breakdown of the 
common mutations found in ADCs and SqCCs.17 
The epidermal growth factor receptor (EGFR) is perhaps the most famous target of 
therapy in lung cancer. EGFR is a tyrosine kinase found at the cell surface membrane 
of most epithelial cells. Upon binding of its ligand, epidermal growth factor (EGF), 
EGFR (also known as ErbB1) forms active homodimers or heterodimers with other 
members of its family (e.g. ErbB2 and ErbB3). EGFR dimerisation results in the 
activation of its tyrosine kinase domain and initiates signal transduction through its 
downstream targets, resulting in the activation of cell survival, proliferation and 
differentiation pathways (see figure 1-4).18  
EGFR mutations are present in approximately 10% of all lung cancers in the United 
States and in 30 to 50% of lung cancers in East Asia.19 EGFR mutation occurs 
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predominantly in adenocarcinoma patients; for example, one study found EGFR 
mutants in 40% of adenocarcinoma patients and only 3% in all other histological 
subtypes, out of a total of 617 NSCLC patients.20 The most common mutations are 
the point mutation L858R and the deletion of exon 19, both resulting in constitutive 
activation of these EGFR mutants. Compared to standard platinum-based 
chemotherapy regimens, these EGFR-activating mutant tumours have shown 
significantly higher susceptibility to treatment with the EGFR tyrosine kinase 
inhibitors (TKIs), erlotinib and gefitinib.21 These EGFR TKIs reversibly compete with 
ATP at its binding site, blocking ATP-dependent trans-phosphorylation and 
preventing the activation of the mutant EGFR dimers.22 The EGFR-specific 
monoclonal antibody cetuximab has also been used to treat patients with EGFR-
mutant tumours. However, treatment with cetuximab was shown to be less effective 
than using gefitinib, possibly because the TKI gefitinib achieves an acute inhibition of 
EGFR signalling, while the signal is only gradually attenuated by the cetuximab 
monoclonal antibody.23 EGFR TKIs are now used as the standard treatment for 
patients suffering from locally advanced or metastatic NSCLC with EGFR-activating 
mutations. 
Different EGFR mutants have different degrees of responsiveness to treatment with 
the first-generation TKIs. The EGFR substitution mutation T790M increases the 
affinity of EGFR to ATP, blocking the reversible competitive inhibitors erlotinib and 
gefitinib.24 Tumours with the T790M mutation are generally not suitable for 
treatment with these TKIs, and are considered to have primary resistance to these 
drugs. Additionally, EGFR-mutant tumours that are initially sensitive to erlotinib and 
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gefitinib, such as those harbouring exon 19 deletions and L858R mutations 
mentioned in 1.1.3.1, often develop resistance to these reversible TKIs, due to 
acquisition of a secondary T790M mutation.25 In cases where secondary resistance 
arises, second-line targeted therapy options need to be explored to bypass 
resistance. Afatinib is a second-generation TKI developed for use in tumours with 
acquired resistance to erlotinib and gefitinib. Unlike first-generation EGFR TKIs, 
afatinib binds covalently and irreversibly to the catalytic site in the EGFR tyrosine 
kinase domain. Afatinib has a higher affinity for EGFR and increased potency 
compared to erlotinib and gefitinib when tested in L858R mutants in vitro, and has 
also been shown to be effective in treating erlotinib- and gefitinib-resistant tumours 
harbouring the T790M mutation in in vivo xenograft models.26,27  
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Figure 1-1. Frequency of different mutations in ADC and SqCC 
The EGFR family genes, EGFR, HER-2 and HER-3, KRAS and EML4-ALK mutations are 
most commonly occurring in ADC (A), while FGFR1 and PIK3CA mutations are most 
commonly occurring in SqCC (B).17 [Reproduced with permission from Elsevier.]
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1.1.3.2 EML4-ALK and MET 
Another driver of oncogenesis involves the rearrangement of the anaplastic 
lymphoma kinase (ALK) gene to a position within the microtubule echinoderm-
associated protein-like 4 (EML4) gene. This is most commonly a consequence of an 
inversion event in the short arm of chromosome 2, resulting in the expression of an 
EML4-ALK fusion protein. The EML4-ALK fusion protein contains the N-terminal of 
the EML4 protein and the catalytic domain of ALK. The presence of the EML4 domain 
results in dimerisation of the fusion protein and constitutive activation of the kinase 
domain within ALK. This over-activation of ALK results in dysregulation of 
downstream cell signalling, including the Akt, STAT3 and ERK1/2 pathways.29,30 
EML4-ALK rearrangements are found predominantly in adenocarcinomas, at 
frequencies of approximately 3 to 6%. Despite this relatively low rate, its prevalence 
is significant in young, never-smokers suffering from adenocarcinoma.31 
MET is another receptor tyrosine kinase that has been observed to be overexpressed 
in lung cancers, with one study reporting approximately 60% of NSCLCs showing 
overexpression of MET. MET expression was low or absent in normal lung tissues.32 
MET dysregulation typically arises as a result of increased copy number mutations 
resulting in gene amplification and less commonly, activating mutations of the MET 
gene. Increased MET activity causes concurrent increases in signalling through its 
numerous downstream pathways, including RAS, PI3K and ERK pathways, which 
regulate cell survival and proliferation. Crizotinib is a TKI that competitively inhibits 
the catalytic activity of both ALK and MET. Treatment with crizotinib in EML4-ALK 
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mutant tumours showed objective response rates of 51 to 61%, significantly higher 
than treatment with standard platinum-based chemotherapy regimens, which have 
objective response rates of less than 10%.33 Crizotinib has been shown to inhibit 
oncogenic proliferation in vitro and in in vivo mouse xenografts.34 Phase III clinical 
trials comparing the effects of crizotinib versus standard chemotherapy in patients 
with MET- and ALK-mutated tumours are on-going. 
 
1.1.3.3 Members of the RAS-RAF-MEK-ERK pathway  
The RAS-RAF-MEK-ERK pathway regulates cell proliferation and differentiation (see 
figure 1-1) and some of its members are frequently mutated in lung cancer settings. 
As such, targeting this pathway at different points is a major strategy in treating 
some subsets of lung cancer, particular ADCs, where these mutations predominantly 
occur. Activation of various mutations in the KRAS gene is one of the most 
commonly occurring events in lung cancer, with a recent study estimating incidences 
of 34% in ADC and 6% in SqCC.35 KRAS is a member of the RAS family of proto-
oncogenes, and is an early, upstream member of the RAS-RAF-MEK-ERK pathway 
(see figure 1-2). KRAS-mutants have been described to have a lower response to 
standard chemotherapy treatment compared to KRAS-wild type tumours. KRAS-
mutant tumours have also shown diminished response rates to treatment with EGFR 
TKIs, as KRAS is downstream of EGFR in the signalling cascade.36 As such, approaches 
that target mutated KRAS in lung cancer are important to improve outcomes in this 
subset of patients. However, efforts in developing effective inhibitors of mutant 
KRAS have been thus far unsuccessful, due to the complexity of KRAS action in its 
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signalling capacity. The various mutations in KRAS alter its activity and function in 
different ways, making it difficult to develop a single inhibitor to target all KRAS 
mutant variants.37 Instead, approaches to inhibit downstream signalling targets of 
KRAS have seen more promising results.  
One such downstream target of KRAS signalling is the mitogen-activated protein 
kinase kinase, or MEK, also commonly known as MAPKK (see figure 1-2). The MEK 
inhibitors selumetinib and trametinib bind to an allosteric site in MEK and reduce its 
affinity for ATP in its catalytic domain. Pre-clinical data showed that MEK inhibition 
by selumetinib suppressed tumour growth in in vivo mouse xenogafts with KRAS-
mutant lung tumours.38 However, a phase two clinical study found that treatment 
with selumetinib had no significant benefit compared to treatment with standard 
chemotherapy in KRAS-mutant tumours.39 However, selumetinib showed a 
significantly higher rate of response in KRAS-mutant tumours when treated in 
conjunction with the chemotherapy drug docetaxel, compared to treatment with 
docetaxel with placebo. Unfortunately, the selumetinib group also experienced more 
negative side effects compared to the placebo group, and further research is 
warranted.40 Multiple clinical trials are currently underway, evaluating the effect of 
treatment with the MEK inhibitors selumetinib and trametinib with a combination of 
other drugs, including EGFR TKIs and conventional chemotherapeutic agents.41 
Another target of interest in the RAS-RAF-MEK-ERK pathway is BRAF, which is a 
member of the RAF family of protein kinases that act downstream of RAS and 
upstream of MEK in the signalling cascade (see figure 1-2).42 BRAF mutations occur in 
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1 to 3% of lung cancer tumours, predominantly in ADCs. Mutations in BRAF, KRAS 
and EGFR were found to be mutually exclusive to each other.43 BRAF mutations are 
activating, and result in constitutive activation of MEK. BRAF mutations are most 
commonly found in melanomas (up to 50% of cases), and most research into BRAF 
inhibitors have therefore been performed in the context of melanoma treatment. In 
melanomas, the V600E substitution accounts for about 90% of all BRAF mutants, and 
the majority of inhibitors target this particular mutant.44,45 Preliminary results of a 
phase II clinical trial reported a 40% objective response rate in lung cancer V600E 
mutants treated with the specific inhibitor dabrafenib, initially designed for use in 
V600E-mutated melanomas.46 Although dabrafenib was shown to be effective in 
treating V600E mutants, lung cancers have been shown to have a much lower 
incidence of this particular mutant, with one study reporting that they only 
accounted for 50% of BRAF-mutated tumours, while other substitutions, G469A and 
D594G, accounted for 39% and 11% respectively.47 Therefore, it is important to 
conduct research to target these other lung-specific BRAF-mutant variants. 
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1.2 Circulating tumour cells (CTCs) 
1.2.1 CTCs in metastasis 
The progression from local to advanced cancer causes a significant reduction in 
patient survival, and the main cause of cancer-related deaths is due to metastatic 
cancer. Understanding the mechanisms of metastasis is therefore important to 
identify strategies to reduce cancer progression. The discovery of tumour-like cells in 
blood was first reported in 1869, during an autopsy of a patient suffering from 
advanced metastatic cancer.48  
Circulating tumour cells (CTCs) are tumour cells that have escaped the primary 
tumour microenvironment and entered the bloodstream. CTCs that have circulated 
in the blood and reached distant organs are then called disseminated tumour cells 
(DTCs). Contrary to the traditional view that metastasis is a late-stage event, recent 
evidence suggests that the dissemination of tumour cells from the primary tumour 
site does not only occur in the later stages of tumour progression, but also from 
early pre-neoplastic lesions.49,50 This evidence supports a parallel model of tumour 
metastasis, which theorizes that DTCs from early stage tumours remain dormant in 
distant secondary sites until genetic progression of these DTCs at a later stage results 
in malignancy and overt metastasis. In this model, the primary and secondary 
tumours progress independently and would be genetically different from each 
other.51 This model also supports the idea of self-seeding, where DTCs return to the 
primary tumour site, causing increased malignancy or tumour recurrence.52,53  
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Another  important  theory  in  cancer  metastasis  is  Paget’s  “seed  and  soil”  pattern  of  
metastasis. This theory was formulated in response to the observation that different 
types of cancers show organ-specific patterns of metastasis. For example, primary 
colorectal caricnoma patients often develop metastases in the liver and primary 
breast carcinoma patients often develop metastases in the bone, brain, liver and 
lung.   According   to   the   “seed   and   soil”   theory,   metastases   only   occur   when   the  
“seed”,  the  CTCs  or  DTCs,  has  a  specific  affinity  for  the  microenvironment  it  is  in,  the  
“soil”.54 This special affinity could come in the form of specific cell surface markers 
on the CTCs/DTCs55, and the response of these CTCs/DTCs to tissue-specific 
chemotactic agents56 or the response to tissue-specific growth conditions.57  
 
1.2.2 CTC detection  
CTCs are present in the blood at very low numbers, at approximately one per 105 to 
107 mononuclear cells in metastatic patients.58 Current techniques utilize a number 
of different approaches to isolate CTCs from peripheral blood, and most of these 
techniques differ in their CTC enrichment step and CTC detection step. CTC 
enrichment from peripheral blood can be carried out in a number of ways. Antibody-
dependent enrichment is the most commonly used system. EpCAM-dependent 
isolation systems are popular, because EpCAM is known to be highly overexpressed 
in the majority of epithelial carcinomas.59 Antibody-dependent systems are 
attractive as detection and quantification are possible without cell lysis. The only US 
Food and Drug Administration-approved CTC isolation system in the market is 
CellSearch, which uses microbeads coated with EpCAM-specific antibodies to pull 
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EpCAM-positive circulating tumour cells from the blood.60 Another EpCAM-
dependent system for CTC isolation utilizes a microfluidic chip. Blood flows through 
the chip, past channels coated with EpCAM antibodies, trapping EpCAM-positive 
cells in the blood as they pass through.61 
However, CTCs are known to be a heterogeneous mixture of cells, and evidence 
suggests that a fraction of CTCs undergo epithelial to mesenchymal transition (EMT), 
causing these cells to acquire mesenchymal characteristics and lose epithelial 
characteristics. EpCAM expression is one such epithelial characteristic that may be 
lost on some CTCs. As a result, EpCAM-based enrichment techniques would only 
succeed in isolating a subset of all CTCs.62,63 Other antibody-independent techniques 
also exist for CTC enrichment and isolation, each with their own benefits and 
disadvantages. Another attractive approach to CTC isolation utilizes differences in 
physical characteristics between CTCs and blood cells. A CTC isolation system 
utilizing differences in cell density is in the early stages of development.64 More 
commonly, CTCs are enriched using size-dependent methods. The most well known 
size-dependent approach is the Isolation by Size of Epithelial Tumour Cell (ISET) 
method, which involves filtering blood through a membrane reticulated with 
cylindrical pores 5-8µm in diameter. ISET relies on the relatively larger size and 
greater rigidness of CTCs compared to the smaller, more deformable blood cells, 
allowing retention of CTCs on the membrane upon filtration.65 Two different 
companies, Rarecells and ScreenCell, have created devices for size-dependent CTC 
isolation, based on the principle of the ISET. The Rarecell system uses a micropump 
to generate a pressure gradient for blood filtration through the membrane, while 
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ScreenCell’s  device uses a vacutainer to enable filtration through the membrane.66,67 
Another size-dependent approach that does not utilize an ISET membrane,  involves 
a microfluidic chip with traps that retain CTCs based on their larger size and relative 
lack of deformability. The Clearbridge Biomedics CTChip is one such microfluidic size-
dependent filtration system. It contains small microposts, arranged to form crescent-
shaped traps 20 µm in diameter, with gaps of 5µm between microposts. This allows 
blood cells to pass through the gaps between the microposts and CTCs to be 
retained in the crescent-shaped traps.68,69 Both ScreenCell and Clearbridge isolation 
platforms were used in this study. Table 1-2 compares the ScreenCell and 
Clearbridge isolation platforms to the FDA approved CellSearch system. 
Following CTC enrichment, a number of different methods are then used to confirm 
if the isolated cells are indeed CTCs. Immunostaining is commonly used to confirm 
the presence of epithelial or cancer markers on the isolated cells. The CellSearch 
protocol, for example, stains for CD45 and cytokeratins, and defines CTCs as EpCAM-
positive, cytokeratin-positive and CD45-negative.60 This is based on the theory that 
CTCs would have epithelial characteristics, such as cytokeratin expression, and would 
therefore fail to recognise CTCs with mesenchymal characteristics. Other strategies 
include microscopic visualisation, RT-PCR and fluorescence in situ hybridisation, for 
identifying mutations in targeted genes.70  
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Table 1-2 . Comparison of CellSearch, Clearbridge Biomedics CTC0 and ScreenCell 
Cyto CTC isolation platforms 
 
CellSearch 
Clearbridge 
Biomedics CTC0 ScreenCell Cyto 
 
CTC isolation 
method 
 
Immunomagnetic 
isolation using 
EpCAM antibody-
coated microbeads 
 
Microfluidic 
filtration through 
permeable traps on 
a microchip 
 
Isolation by Size of 
Epithelial Tumour 
cells (ISET) through 
a permeable 
membrane 
Selection 
principle 
EpCAM-positive 
CTCs 
CTCs are larger and 
less deformable 
than blood cells 
CTCS are larger and 
less deformable 
than blood cells 
Volume of blood 
processed 
7ml 
 
1ml 3ml 
Advantages x FDA approved 
x Good 
preservation of 
cell morphology 
x Non-antigen-
dependent 
isolation 
x Trapped cells 
can be visualised 
during process 
of microfiltration 
 
x Non-antigen-
dependent 
isolation 
x Good 
preservation of 
cell morphology 
Disadvantages x Only EpCAM-
positive CTCs 
isolated 
x Skewed towards 
epithelial CTCs 
(EpCAM 
positivity is an 
epithelial 
characteristic) 
x CTCs may not be 
heterogeneous 
in size and 
deformability 
x Skewed towards 
isolating large 
and rigid cells, 
i.e. CTCs with 
epithelial 
characteristics 
x Poor 
preservation of 
cell morphology 
due to high 
shear stress 
during 
microfiltration 
x CTCs may not be 
heterogeneous 
in size and 
deformability 
x Skewed towards 
isolating large 
and rigid cells, 
i.e. CTCs with 
epithelial 
characteristics 
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1.2.3 Clinical relevance of CTCs in lung cancer 
In 2009, using CellSearch for CTC isolation, CTCs were detected in 31% of primary 
lung cancer patients and 12% of patients with non-malignant disease, in a sample 
size of 150 patients. While the results did not show a significant difference in 
distinguishing patients with lung cancer and those without, CTC counts increased 
significantly, with increasing stage of cancer, especially in advanced cancers and 
SCLCs, which are characteristically more systemically spread.71 A study measuring 
CTC counts in 50 SCLC patients found that 86% had a CTC count of more than 2, with 
a median count of 28, before administration of standard chemotherapy. Following 
treatment, CTCs could only be detected in 60% of patients, compared to 86% before 
treatment. CTC counts also had prognostic value, with high CTC counts significantly 
associated with reduced survival.72  
In a study of 101 late stage NSCLC patients, 21% of patients had a baseline CTC count 
of more than 2, with a mean count of 27 in stage III patients and 60 in stage IV 
patients. Prognostically, patients with a lower CTC count before chemotherapy also 
showed a significantly higher progression-free survival.73 Similar results have also 
been reported for other solid tumours, including breast, colorectal and castration-
resistant prostate cancer.74-76 CTC detection and enumeration could also play a role 
in monitoring the efficacy of chemotherapy, and studies have shown that a 
reduction in CTC count post-treatment correlated with longer progression-free 
survival.77,78  
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All the results mentioned above were obtained using the CellSearch CTC isolation 
system. Studies have also been performed, comparing the efficacy of CellSearch and 
ISET in CTC detection. In one study, ISET (Rarecells) detected 2 or more CTCs in 20 
out of 26 late-stage NSCLC patients, compared to only 6 out of 26 patients using 
CellSearch. In the same pool of stage IV patients, ISET also produced a much higher 
CTC count compared to CellSearch; 127 versus 10, per 7.5ml of blood respectively. 
ISET was able to detect CTCs with non-epithelial markers, underscoring the 
advantages of antibody-independent CTC isolation.79 An ISET study of 208 pre-
operative   NSCLC   patients   and   39   healthy   control   patients   found   ‘circulating   non-
haematological  cells’   (CNHC)   in  49%  of  the  NSCLC  patients  and  none   in  the  healthy  
group. Additionally, 36% of the NSCLC patients had CHNCs with cytological 
characteristics of cancer cells (CTCs).80  
Mutation testing is another possible application following CTC isolation. One study 
used CTC-Chip, a microchip with EpCAM antibody-labelled microposts, to isolate 
CTCs from 12 patients with metastatic NSCLC with known EGFR mutations. EGFR 
mutation analysis was performed on these CTCs as well as on free plasma DNA 
extracted from the same patients, using the scorpions amplification refractory 
mutation system (scorpion ARMS), a method of mutation testing with high mutation 
detection capability. EGFR mutation was detected in 11 out of 12 patients using CTCs 
and in only 4 out of 12 patients using free plasma DNA.81 BRAF mutations testing in 
CTCs was also investigated in melanoma studies, where BRAF mutation occurs at a 
high frequency. In one study, the BRAF-V600E mutation was detected in CTCs in 77% 
of patients with tumours harbouring the mutation.82 In another BRAF study in 
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melanoma, BRAF mutational status was concordant between tumour and CTCs in 6 
out of 9 patients tested.83  
Mutation testing was also performed on CellSearch-isolated CTCs from metastatic 
colorectal patients with KRAS wild-type and mutant genotypes, with a detection 
frequency of 16.7% and 45% respectively.84 Another study of metastatic colorectal 
patients found KRAS-positive CTCs in 17 out of 23 patients with KRAS mutated 
tumours, and one patient with wild-type KRAS tumour was found with KRAS-positive 
CTCs.85 In NSCLC, KRAS mutation status concordance between tumour and ISET-
Isolated CTCs was found to be 52% in a sample of 92 patients.86 Discrepancies 
between the mutational status of the primary tumour and CTCs in the results 
reported above may exist due to experimental limitations, or may reflect real 
differences in the mutational states of primary tumours and metastases. 
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1.3 The epithelial cell adhesion molecule (EpCAM)  
1.3.1 EpCAM structure and function in adhesion 
The epithelial cell adhesion molecule (EpCAM), also known in published literature as 
17-1A, CD326, TACSTD1 or TROP1, is a transmembrane glycoprotein expressed in 
healthy epithelium and overexpressed in a variety of epithelial cancers. It is 314 
amino acids in length, and comprises a large 30kDa extracellular domain (EpEX), a 
3kDa transmembrane domain and a short 3kDa intracellular domain (EpICD). The 
extracellular domain contains an epidermal growth factor (EGF)-like domain and a 
thyroglobulin domain (figure 1-3).87 In humans, germline mutations in EpCAM cause 
congenital tufting enteropathy (CTE), a rare autosomal recessive disease that 
develops days after birth and carries significant mortality and morbidity. It causes 
intractable diarrhoea, due to the morphologically abnormal development of the 
intestinal epithelium resulting from a lack of cell surface EpCAM expression.88 The 
primary structure of EpCAM is highly conserved across primates, rodents and to a 
lesser extent in amphibians and fishes, once again underscoring its biological 
importance.89 
In healthy epithelia, EpCAM is mainly located near tight junctions of cell-cell contact 
and was traditionally thought to function solely as an adhesion molecule mediating 
homophilic cell adhesion. On its own, EpCAM is a relatively weak cell adhesion 
molecule.90 Its main function is in modulating the strength of adhesion between 
cells, and it has been shown to regulate the activity of other adhesion proteins 
involved in the formation of tight junctions and adherens junctions. EpCAM was 
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found to be an important regulator of tight junction formation, via interaction with 
various claudins, especially claudin-7. EpCAM mutant mice showed significant down-
regulation of claudins 2, 3, 7 and 15, and resulted in the formation of abnormal tight 
junctions.91,92 While this shows the role of EpCAM in contributing to cell adhesion via 
tight junction regulation, EpCAM has also been reported to reduce cell adhesion 
strength via its regulatory role in adherens junctions. Increasing expression of 
EpCAM, while causing no effect on the overall amount of cellular proteins, instead 
reduces the interaction of cadherins, particularly E-cadherin, with the cytoskeleton, 
resulting in abrogation of adherens junctions.90 These counter-intuitive effects of 
EpCAM highlight the complex role of EpCAM on cell adhesion.  
 
1.3.2 EpCAM as a therapeutic target 
EpCAM is highly overexpressed in the majority of epithelial carcinomas compared to 
healthy epithelia, where its expression is no longer restricted to basolateral regions 
of the cell membrane.59 High-level EpCAM expression was reported in 63.9% of lung 
carcinomas (n=1287), and adenocarcinomas had a higher percentage of high EpCAM 
expression compared to carcinomas with squamous characteristics.93 This frequent 
high-level expression of EpCAM on cancer cells, as well as the sequestering of 
EpCAM in relatively inaccessible tight junctions in healthy epithelia, makes it an 
attractive target for therapy. Additionally, its high expression levels in cancer makes 
it a popular marker for targeting and isolating circulating tumour cells, as described 
in section 1.2.  
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Various antibody-driven therapies targeting EpCAM are being developed for use in 
various cancer settings. The principle for using antibody therapy is to 
immunologically label cancer cells for clearance by the cytotoxic cells of the immune 
system. Catumaxomab is a trifunctional, bispecific antibody that targets EpCAM on 
cancer cells and CD3 on cytotoxic T-cells, and also binds to accessory cells such as 
dendritic cells and natural killer cells via its Fc region.94  In theory, Catumaxomab 
brings cancer cells in close proximity to the immune cells required for cancer cell 
lysis. Catumaxomab is used to treat malignant ascites, but has also been tested in a 
phase one clinical trial in NSCLC. While survival outcomes were not the primary 
purpose of the phase one study, they reported favourable survival rates that may 
indicate potential clinical efficacy, which would need to be assessed in future trials.  
Another bispecific antibody to EpCAM and CD3, MT110, has also been shown to be 
effective at inducing lysis of EpCAM expressing cancer cells. MT110 was shown to 
completely prevent subcutaneous colon cancer outgrowth and also completely 
eradicate subcutaneously introduced human metastatic ovarian cancer into 
NOD/SCID mice.95 A phase one clinical trial of MT110 in patients with metastatic 
lung, colorectal or gastric cancer has reported signs of biological activity of the 
treatment, at well-tolerated doses.  
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       Figure 1-3. Structure of EpCAM
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1.3.1 EpCAM cleavage and signalling  
A study in 2009 by Maetzel et al. described the first reported instance of EpCAM 
cleavage in a cancer setting, in this case, in colon and hypopharyngeal carcinoma cell 
lines. They found that EpCAM was cleaved, causing release of its intracellular domain 
(EpICD) and localisation in the cytoplasmic, perinuclear and nuclear regions of the 
cell. They found the cleavage process to be dependent on two proteases frequently 
involved in regulated intramembrane proteolysis: TNF-α  converting  enzyme (TACE) 
and presenilin-2 (PS-2). Both were also found to co-precipitate with full-length 
EpCAM in pull down experiments.  A yeast 2-hybrid screen of EpICD identified four 
and a half LIM domain protein 2 (FHL2) as an interacting partner, and subsequent co-
immunoprecipitation  also  pulled  down  β-catenin as another member of what turned 
out to be a large nuclear complex. Further experiments revealed a large complex 
containing   EpICD,   FHL2,   β-catenin and lymphoid enhance-binding factor 1 (Lef-1). 
This complex translocates into the nucleus and activates downstream E-cadherin and 
Wnt pathway signalling (figure 1-4). It was also discovered that soluble EpEX can act 
as a stimulator of EpCAM cleavage and degree of cell-cell contact is also needed to 
activate cleavage of EpCAM.96,97 
Since this discovery EpCAM proteolysis is relatively recent, only a few other studies 
have been conducted that investigate the occurrence of EpCAM cleavage or the 
specific localisation of its cleavage products in various cancers. A breast cancer study 
in 2014 employed immunohistochemical staining in 266 breast cancer and 45 normal 
breast tissues to assess differences in EpICD expression.  
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Figure 1-4. EpCAM cleavage and signalling 
Figure 1-4a depicts an EpCAM protein with arrows indicating cleavage positions by 
the membrane proteolytic enzymes TACE and PS-2. Figure 1-4b shows the signalling 
pathways involved via EpCAM cleavage and release of EpICD. EpICD interacts with a 
host of signal transduction proteins and translocates into the nucleus, activating 
transcription of c-myc as well as epcam, effectively establishing a positive-feedback 
EpCAM expression loop.96 [Reproduced with permission from Nature Publishing 
Group.]
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Examination of lung tissues for EpICD expression showed that nuclear EpICD was 
more frequently expressed in cancer tissue compared to normal tissue. There was 
also a significant reduction in disease-free survival with increased nuclear EpICD 
expression.98 A large multi-tissue microarray study investigated the loss of 
membrane-bound EpICD in different tumour types. Figure 1-5 shows a breakdown of 
their findings. Lung cancer showed a relatively low proportion of EpICD cleavage 
(25%) compared to full length EpCAM, while endometrial and bladder cancers 
showed the highest level of EpICD cleavage (more than 50%). Interestingly, 
bronchoalveolar lung carcinomas showed abnormally high EpICD cleavage of 80%.99  
 
 
 
48 
 
      Figure 1-5. Ratio of full-length EpCAM
 to EpICD
-cleaved EpCAM
 expression in different epithelial cancers 
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1.4 Hypothesis and aims 
I hypothesised that 1) isolation of circulating tumour cells as an indicator of lung 
cancer, stage and prognosis would be most usefully determined using antibody-
independent methods and 2) that the mechanism of EpCaM cleavage would be the 
same as that described for other tumour cells e.g. gut and breast, and therefore 
useful in understanding mechanisms of lung cancer and its treatment. 
 Thus, firstly, I wanted to test the feasibility of two antibody-independent CTC 
isolation platforms for 2 purposes: to retrieve CTCs for subsequent molecular 
analysis and to detect CTCs for diagnosis of lung cancer. I investigated the 
Clearbridge CTChip system, which is a microfluidic size-dependent CTC isolation 
platform, as well as the ScreenCell Cyto device which utilises a porous membrane 
device to isolate CTCs based on the principle of ISET.  
Secondly, I investigated whether EpCAM cleavage occurs in lung cancer cells in a 
similar process to that described previously in section 1.3.1. There were no 
published data reporting EpCAM cleavage in lung cancer, and I wanted to determine 
if EpCAM cleavage occurs in lung cancer, and if so, if it proceeds in the same manner 
as reported in breast and colon cancer. I also wanted to find out the effect that 
EpCAM cleavage has on tumorigenicity of lung cancer cells, specifically with regards 
to changes in cell proliferation and migration. 
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2 MATERIALS AND METHODS  
2.1 Materials 
2.1.1 Blood collection and CTC staining 
K2EDTA spray-coated vacutainer BD, #368857 
Harris’  Haematoxylin Sigma, #HHS-80 
Eosin-Y Merck, #1.09844 
Faramount aqueous mounting medium Dako, #53025 
 
2.1.2 Cell Lines  
H358 Lung adenocarcinoma ATCC, #CRL-5807 
A549 Lung adenocarcinoma Lab stocks 
 
2.1.3 Cell culture reagents 
Dulbecco’s  Modified  Eagle  Medium  (DMEM) Sigma, #D6546 
RPMI-1640 Sigma, #R0883 
Fetal Bovine Serum PAA, #A15-101 
Penicillin-streptomycin-L-glutamine solution Gibco, #10378-016 
Trypsin-edta Sigma, #T4049 
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2.1.4 Tissue/cell lysis and protein quantification 
PBS Sigma, #D8537 
10X Cell Lysis Buffer Cell Signaling, #9803 
Complete Mini protease inhibitor Roche, #04693159001 
Bradford reagent Sigma, #B619 
 
2.1.5 SDS-PAGE 
4-12% Bis-Tris Protein Mini Gels Life Technologies, #NP0321 
4X LDS Sample Buffer Life Technologies, #NP0008 
10X Reducing Agent Life Technologies, #NP0009 
NuPAGE MOPS SDS Running Buffer Life Technologies, #NP0001 
Novex Sharp Pre-stained protein standard Life Technologies, #LC5800 
Magic Mark XP Life Techonoligies, #LC5602 
 
2.1.6 Immunoblotting 
TBS (10X) 
24.2g Trizma HCl 
80.1 NaCL 
Mix in 800ml distilled water, pH to 
7.6 with pure HCl and top up with 
distilled water to 1L 
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TBST (1X) 
100ml of TBS (10X) 
900ml distilled water 
1ml Tween-20 
iBlot Transfer Stack, nitrocellulose, mini Life Technologies, #IB301002 
ECL Prime Western blotting reagent GE Healthcare, #RPN2232 
Super RX Medical Xray Film Fuji, #RF12 
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2.1.7 
Antibodies  
2.1.7.1 
Im
m
unoblotting 
Antibody 
Abbreviation 
Antigen 
Source 
W
orking 
dilution 
Com
pany 
EpCAM
 (C-10) 
α-EpEX 
N
-term
inus of EpCAM
 
M
ouse 
m
onoclonal 
1:4000      
Cell Signaling, #sc-25308 
EpCAM
 (C-term
) 
α-EpICD 
C-term
inus of EpCAM
 
Rabbit 
m
onoclonal 
1:3000        
Epitom
ics, #1144-1 
β-tubulin (9F3) 
α-tubulin 
N
-term
inus  of  β-tubulin 
Rabbit 
m
onoclonal 
1:5000 
Cell Signaling, #2128 
α-m
ouse-HRP 
2° α-m
ouse 
IgG from
 m
ouse serum
 
Goat 
1:3000 
Dako, #P0447 
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polyclonal 
α-rabbit-HRP 
2° α-rabbit 
IgG from
 rabbit serum
 
Goat 
polyclonal 
1:3000 
Dako, #P0448 
α-m
ouse             
IP beads 
TrueBlot                    α-
m
ouse IP beads 
IgG from
 m
ouse serum
 
Goat 
polyclonal 
- 
Rockland, #18-8811-25 
α-rabbit               
IP beads 
TrueBlot                    α-
rabbit IP beads 
IgG from
 rabbit serum
 
Goat 
polyclonal 
- 
Rockland, #00-8800-25 
IP  α-m
ouse-HRP 
TrueBlot 2° α-m
ouse 
IgG from
 m
ouse serum
 
Goat 
polyclonal 
1:10000 
Rockland, #18-8811-25 
IP  α-rabbit-HRP 
Trueblot 2° α-rabbit 
IgG from
 rabbit serum
 
Goat 
polyclonal 
1:10000 
Rockland, #18-8816-31 
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2.1.7.2 
Im
m
unofluorescence staining 
Antibody 
Abbreviation 
Antigen 
Source 
W
orking 
dilution 
Com
pany 
EpCAM
 (C-10) 
α-EpEX 
N
-term
inus of EpCAM
 
M
ouse 
m
onoclonal 
1:100      
Cell Signaling, #sc-25308 
EpCAM
 (C-term
) 
α-EpICD 
C-term
inus of EpCAM
 
Rabbit 
m
onoclonal 
1:100        
Epitom
ics, #1144-1 
VU
1D9 
- 
N
-term
inus of EpCAM
 
M
ouse 
m
onoclonal 
1:100 
Abcam
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2.1.8 Tissue FFPE processing and staining 
Access Super (pH 9.5) heat retrieval solution Menarini, #MP-606-PG1 
Prolong Gold Antifade mountant with DAPI Life Technologies, #P36931 
Prolong Gold Antifade Life Technologies, #P36930 
TO-PRO-3 Iodide Life Technologies, #T3605 
 
2.1.9 TACE and PS-2 inhibition assays and recombinants 
TAPI-2  Enzo, #BML-PI135-001 
DAPT  Sigma, #D5942-5MG 
Recombinant TACE R&D systems, #930-ABD-010 
 
2.1.10 Bacterial culture and analysis 
Escherichia coli from Dr Zhang Youming 
EpCAM-GFP in pCMV6-AC-GFP vector Origene, #RG201989 
pCMV6-AC-GFP vector Origene, #PS10010 
LB broth Sigma, #L2542 
Ampicillin sodium salt Sigma, #A9581 
Agar Sigma, #A5306 
QIAprep spin miniprep kit Qiagen, #27101 
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XhoI restriction enzyme Promega, #R6161 
SgfI restriction enzyme Promega, #R7103 
Tris-Borate-EDTA buffer Sigma, #T4415 
GelRed nucleic acid gel stain Biotium, #41001 
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2.2 Methods 
2.2.1 Blood collection  
Patients with known or suspected primary lung cancer were identified at the Royal 
Brompton Hospital at least 1 day before their surgical procedures were schedule to 
take place. Patient consent was obtained and donated blood collected with the 
assistance of the National Institute of Health Biomedical Research Unit Advanced 
Disease Biobank (NRES 10/H0504/9). 3ml of blood was collected from the central 
line of each prospective patient immediately before surgery, in a K2EDTA spray-
coated vacutainer, discarding the first 1ml of blood to exclude epithelial and 
endothelial cells from the blood samples. Blood samples were stored upright at 4°C 
and processed within 6 hours of collection.  
 
2.2.2 Tissue collection  
Primary tissue was obtained from lung cancer patients undergoing surgical 
resections at the Royal Brompton Hospital, with the help of National Institute of 
Health Biomedical Research Unit Advanced Disease Biobank (NRES 10/H0504/9). 
Matched tissue samples were obtained from the tumour as well as from surrounding 
healthy tissue in each patient, ranging from approximately 100 to 400mg in weight 
per tissue sample.  
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2.2.3 Tissue lysate preparation 
Each tissue sample was washed with PBS, using a sterile 0.3mm hypodermic needle 
to flush the blood out of the tissue - typically requiring 5 to 10 volumes of 10ml of 
PBS. 1X cell lysis buffer was freshly prepared, supplemented with Complete Mini 
protease inhibitors and kept chilled at 4°C. Each tissue sample was suspended in 1X 
cell lysis buffer in a 1:8 tissue to buffer ratio (weight/volume) and minced finely 
using scissors. Each sample was then sonicated on ice for 4 cycles of 5s, at 1minute 
intervals between cycles to prevent overheating, and then left to incubate on ice for 
half an hour. After incubation, the sample was centrifuged at 15,000G for 15 minutes 
at 4°C and the supernatant containing the tissue lysate removed. Where possible, 
tissue lysates were aliquoted before storage at -80°C. 
 
2.2.4 Cell lines, culture and maintenance 
The human lung adenocarcinoma cell line A549 was obtained from lab stocks and 
cultured  in  Dulbecco’s  Modified  Eagle  Medium  supplemented  with  10%  fetal  bovine  
serum and 10% penicillin/streptomycin/L-glutamine. The human lung 
adenocarcinoma cell line H358 was obtained from ATCC and cultured in RPMI-1640 
medium supplemented with 10% Fetal Bovine Serum and 10% 
penicillin/streptomycin/L-glutamine. Cells were incubated in humidified 5% CO2 at 
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37°C. Approximately 1 million cells for were seeded into a T75 flask and allowed to 
reach 70% confluency before subculturing, replenishing the culture medium every 2 
days.  
Subculturing was performed by first washing the adherent cells with PBS three times 
before carrying out enzymatic detachment using a trypsin-edta solution for 5 
minutes at 37°C or until cell detachment occurred. The resulting cell suspension was 
then centrifuged at 150G for 10 minutes, the trypsin-EDTA solution discarded and 
the cell pellet resuspended in complete medium (with antibiotics and L-glutamine), 
before re-seeding into fresh flasks at appropriate dilutions. Frozen stocks of each cell 
line at early passage numbers were kept in liquid nitrogen and experiments were 
performed on cells lower than passage number 30. 
 
2.2.5 Cell culture lysis 
Adherent cells were washed with PBS three times. Cells were then mechanically 
detached from the culture plate surface using a cell scraper. Detached cells were 
then resuspended in PBS and cell numbers counted using a haemocytometer. The 
cell suspension was then centrifuged at 150G for 10 minutes at 4°C to pellet the 
cells. 1X cell lysis buffer was freshly prepared, supplemented with Complete Mini 
protease inhibitors and kept chilled at 4°C. After centrifugation, the supernatant was 
discarded, the cell pellet resuspended in 1X cell lysis buffer and incubated on ice for 
half an hour. This was followed by centrifugation at 15,000G for 15 minutes at 4°C to 
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pellet the cell debris. The supernatant, containing the cell lysate, was collected in a 
chilled Eppendorf tube and kept at 4°C for short term use, or stored at -80°C for up 
to 3 months. Cell lysates were aliquoted into smaller volumes before freezing at -
80°C, to prevent protein degradation due to freeze-thaw cycles. 
 
2.2.6 Bradford assay for determining protein concentration of lysates 
Stocks of 1mg/ml Bovine Serum Albumin (BSA) were prepared in 1ml aliquots and 
stored at -80°C prior to use as a control sample for standard curve generation. In a 
96-well plate, wells of 0, 1, 2, 3, 4, 5, 7.5 and 10mg/ml of BSA were prepared in 
triplicate. Wells containing 2Pl of lysate of unknown concentration were also 
prepared in triplicate. 200Pl of ready-to-use Bradford reagent was mixed into the 
samples in each well and incubated at room temperature for 5 minutes. Absorbance 
at 595nm was then measured using a microplate spectrophotometer and the OD 
readings of BSA plotted on a standard curve. If the R2 value of the standard curve 
was less than 0.9, the BSA standards were prepared and assayed once again. The OD 
readings of the lysates were used to determine their protein concentrations using 
the standard curve. 
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2.2.7 SDS-PAGE 
The Novex NuPAGE SDS-PAGE system and 4-12% Bis-Tris Protein Mini Gels were 
used to run protein gel electrophoresis. Prior to gel loading, cell or tissue lysates 
were mixed with 4X LDS sample buffer, 10X Reducing agent, made up to a 20Pl total 
volume with distilled water before heating at 90°C for 5 minutes. Each sample to be 
loaded contained 20Pg of total protein per well unless otherwise stated. Samples 
were loaded into the gels and run in NuPAGE MOPS SDS Running Buffer at 200V for 
approximately 35 minutes, or until optimal band separation was achieved.  
 
2.2.8 Immunoblotting 
Proteins were transferred from the NuPAGE mini gel to a nitrocellulose membrane 
using the iBlot dry blotting system. Upon protein transfer after 7 minutes, the 
membrane was blocked in 5% milk/TBST for 1 hour at room temperature. The 
membrane was then rinsed with TBST to remove traces of milk, before incubation 
with primary antibodies overnight at 4°C. Primary antibodies were diluted in a 
solution of 5% milk/TBST. The following day, the membrane was washed in three 
volumes of TBST, for 15 minutes each, before incubation with secondary antibodies 
for 1 hour at room temperature. Secondary antibodies were diluted in a solution of 
5% BSA/TBST. After 1 hour, the membrane was washed in three volumes of TBST, for 
15 minutes each. Antibodies were diluted at the appropriate ratios, depending on 
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the specific antibodies (see 2.1.7). Blocking, antibody incubation and wash steps 
were all carried out with gentle agitation on an orbital shaker set to low speed.  
Chemiluminescent detection of bands was carried out using ECL Prime Western 
blotting reagent. Solution A and B were mixed together in a 1:1 ratio, pipetted 
directly on onto the membrane surface and left to incubate at room temperature for 
1 minute. Subsequently, the membrane was wrapped in cling film and secured in a 
film cassette. In a dark room, photosensitive film was exposed to the membrane in 
the film cassette. Exposure times varied from 5 seconds to 20 minutes, depending on 
the intensity and clarity of the bands produced.  
 
2.2.9 Fomalin-Fixed Paraffin Embedding (FFPE) and heat induced epitope 
retrieval 
FFPE was carried out with the help of the pathology department of the Royal 
Brompton Hospital. Tissue samples were rinsed in PBS and fixed in buffered formalin 
overnight and rinsed in running tap water for 1 hour. The tissue was then 
dehydrated by sequentially immersing in 70%, 80% and 90% ethanol for 45 minutes 
each, followed by 100% ethanol, three times for an hour each. The tissue was 
immersed in xylene twice, then paraffin three times, for an hour each time. The fixed 
tissue was then embedded in a paraffin block and stored at room temperature 
before microtome sectioning. Slides were prepared with tissue sections of 5um 
thickness and kept at room temperature. 
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Prior to antigen retrieval, the sections were first baked at 60°C for an hour. To carry 
out heat induced epitope retrieval, the slides were immersed in Access Super heat 
retrieval solution in a heat-resistant polypropylene Coplin jar and heated at 95°C for 
30 minutes in a pressure cooker. Slides were washed in tap water prior to 
immunofluorescent staining. 
 
2.2.10 Immunofluorescence staining  
Cells lines were grown on chamber slides to facilitate staining. Cells were first fixed 
in a 4% paraformaldehyde solution for 10 minutes at room temperature followed by 
3 washes in PBS. Tissue sections were first ringed using a PAP pen to contain staining 
reagents within the hydrophobic barrier. While staining tissue sections, all 
incubation steps were performed in a humidified chamber to prevent evaporation of 
the buffers from the slide. 
The cell or tissue samples were blocked in 1% BSA/PBS for an hour before incubating 
with the primary antibody overnight at room temperature. The next day, the 
samples were washed thoroughly in PBS and incubated with secondary antibody for 
an hour in the dark at room temperature, followed by a final thorough wash in PBS. 
Where more than 1 primary antibody was used in a sample, they were incubated 
sequentially and not concurrently. The sections were mounted using Prolong Gold 
Antifade mountant with DAPI when single or double staining was carried out. When 
a sample was triple stained, TO-PRO-3-iodide was used instead of DAPI as a nuclear 
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stain. The sample was incubated with 1PM of TO-PRO-3 iodide for 15 minutes before 
mounting with Prolong Gold Antifade mountant (without DAPI). Stained samples 
were stored in the dark at 4°C until microscopic analysis. 
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3 CIRCULATING TUMOUR CELLS: A MODEL FOR METASTASIS AND TARGET 
FOR NON-INVASIVE LUNG CANCER DETECTION 
 
3.1 Introduction 
Of the total number of cancer-related deaths, 90% are due to metastatic disease.100 
It is therefore not surprising that there has been increasing interest in the detection 
and characterization of circulating tumour cells (CTCs) in recent years. CTCs are very 
rare cells of tumour origin, accounting for 1 in 105 to 107 mononuclear cells in the 
blood of a cancer patient.58 The recent spike in CTC research has also seen the re-
emergence  of  Paget’s  “seed  and  soil”  theory  of  metastasis  come  to  prominence.  This  
model was proposed in an attempt to address the observation that different primary 
cancers tend to preferentially metastasize to specific organs. Paget theorized that a 
subset   of   cells,   the   ‘seed’,   is   disseminated   from   the   primary   tumour   with   the  
potential to establish and grow, but will establish secondary tumours only in specific 
sites that contain the right microenvironment required by these cells to thrive, the 
‘soil’.101 As cells of neoplastic origin with the potential to reach distant parts of the 
body, CTCs are thought to play a role in blood-borne metastasis through an as yet 
undefined mechanism. 102 
In a 2004 study of the expression of the epithelial cell adhesion marker (EpCAM) in 
lung tumours, EpCAM was found to be expressed in 94% of squamous cell 
carcinomas, 85% of adenocarcinomas and 83% of SCLCs.59 Because of this high 
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frequency of EpCAM expression in tumour cells, the overwhelming majority of CTC 
isolation technology available currently relies on EpCAM-dependent capture of CTCs. 
Arguably, the most widely used of these and the only one to have been approved by 
the Food and Drug Administration is the CellSearch system by Veridex. CellSearch 
employs immunomagnetic enrichment using ferrofluid particles as a means of 
isolating CTCs. After CTC capture, the cells are stained for cytokeratin 8, 18 and 19, 
CD45 (a lymphocyte marker) and 4,6- diamidino-2-phenylindole (DAPI, a nuclear 
dye). CTCs are defined as positive for DAPI and cytokeratin but negative for CD45.103  
Another approach to CTC capture involves the use of a microfluidic device, called a 
herringbone-chip. The first incarnation of this chip consisted of 78,000 microposts 
coated with EpCAM antibodies (EpCAM Ab), similar to the CTC isolation principle in 
the CellSearch system. In this model, the blood flows past the posts in a microfluidic 
environment and EpCAM-positive CTCs stick to the EpCAM Ab-coated posts as 
though they are Velcro. The latest generation herringbone-chip has etched chevrons 
instead of microposts, which result in microfluidic channels shaped like herringbone 
(see figure 3-1, A). The principle is the same, but the design of the chip creates 
‘microvortexes’,  which  increases  physical  interactions  between  CTCs  and  the  EpCAM  
Ab-coated surfaces.61 
Both the CellSearch and Herringbone-chip systems rely on recognition of EpCAM by 
specific antibodies in their CTC isolation steps. Although EpCAM has been shown to 
be highly expressed in many carcinomas, as described previously, there are subsets 
of CTCs that are EpCAM negative.63 The use of CellSearch or the Herringbone-chip  
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Figure 3-1. CTC isolation platforms 
 
A: The new generation Herringbone-chip.   The   chevrons   create   “microvertexes”  
when blood flows through, allowing for greater interaction between CTCs and the 
EpCAM-Ab-coated walls.61 [Reproduced with permission from PNAS open access.] B: 
Clearbridge Biomedics CTChip. The CTC chip consists of an array of 900 traps, each 
consisting of 3 microposts arranged in a crescent shape, with 5µm gaps between the 
posts. Blood flows downward through the chip, trapping CTCs, which are larger and 
more rigid, and letting blood cells, which are smaller and more deformable, pass 
through the gaps. The scale bar represents 20µm.69  [Reproduced with permission 
from Springer.] C: ScreenCell Cyto membrane filter. The filter comprises of a 
permeable membrane with pores of 8µm in diameter. A vacuum is applied across 
the membrane, causing the smaller, more deformable blood cells to flow through 
the gaps and leaving the larger, more rigid CTCs trapped on the surface of the 
membrane. The scale bar represents 20µm.104 [Reproduced with permission from 
the International Institute for Anticancer Research.] 
C 
A B 
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would inevitably result in the exclusion of these EpCAM negative cells from analysis. 
Thus, an EpCAM-independent CTC isolation system would be needed in order to 
include this non-EpCAM-expressing subset in the final count of CTCs.  
The CTC isolation platform developed by Clearbridge BioMedics is one such 
antibody-independent microfluidic system for CTC capture. Their system involves the 
use of a CTC isolation chip, called a CTChip, which comprises 900 traps about  20μm  
in  diameter,  with  5μm  gaps  within the traps (see figure 3-1, B). The principle relies 
on the higher deformability of blood cells compared to CTCs, which are epithelial in 
nature. The red blood cells and platelets pass through the 5µm gaps, macrophages 
and other larger white blood cells squeeze through the gaps, while circulating 
tumour cells are retained in the traps and can then undergo downstream staining 
and analysis. ScreenCell has also developed a Cyto device, which involves passing 
blood through a microporous membrane filter (see figure 3-1, C). The membrane 
filter has pores 6.5µm in diameter, and similar to the Clearbridge Biomedics system, 
separates CTCs from peripheral blood cells based on their size and deformity.  
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3.2 Hypothesis and aims 
I hypothesized that blood-based, EpCAM antibody-independent CTC collection and 
detection would be possible and could be a feasible, non-invasive diagnostic test for 
lung cancer. I therefore investigated CTC isolation using the two EpCAM Ab-
independent platforms described above. My initial aims were two-fold: firstly to 
isolate and retrieve these CTCs in order to perform subsequent molecular analysis on 
them, e.g. EpCAM expression, and secondly, to stain isolated CTCs to examine 
whether a blood-based, antibody-independent diagnostic test for lung cancer could 
be feasible.  
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3.3 Experimental protocols 
3.3.1 Clearbridge Biomedics microfluidic filtration system  
3.3.1.1 Blood processing and CTC capture  
The Clearbridge BioMedics CTC0 capture system prototype comprises a pump-driven 
microfluidic apparatus that allows the flow of blood and secondary reagents through 
a CTC capture chip (CTChip). There are two inlet ports connected to the CTChip by 
tubing, a “blood  port”   for   the  blood   sample   and  a   “secondary  port”   for   secondary  
reagents,   and   one   outlet   port,   “waste   port”,   for   waste   collection.   The   set-up is 
shown in figure 3-1 below.  
Prior to processing the blood through the CTChip, 10mM EDTA was washed through 
the chip via the secondary port for approximately 15 to 30 minutes at 70kPa, to fill 
the chip with liquid and remove air bubbles. At this stage, the blood port was closed, 
by pinch clipping the blood port tubing. Visualisation of the chip was achieved via a 
camera present directly underneath the chip. Once all air bubbles were removed, 
the pressure was lowered to 5kpa. Just prior to processing, the blood was passed 
through  a  40μm  cell   strainer   to   remove  clots.  The   secondary  port  was   then  closed  
and the blood port opened to allow 1ml of blood to wash through the chip to filter 
and trap cells.  
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Figure 3-2. Clearbridge Biomedics CTC0 capture system prototype 
A. CTC0 Capture system set-up, attached to a computer (inset). B. 3 buffer barrels 
(clear liquid reservoirs connected to tubing via green needle tips) connected to the 
chip via 3 ports: 2 inlet ports and 1 outlet port. C. Individual crescent-shaped traps, 
shown here trapping individual MCF-7 cells. Scale bar represents 20μm.69 [A and B 
reproduced with permission from Clearbridge Biomedics; C reproduced with 
permission from Springer.] 
 
A 
B C 
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3.3.1.2 Haematoxylin and eosin staining of trapped cells 
After approximately 2 hours, almost all of the blood had washed through the chip 
and the blood port was closed. The secondary port was then opened, and the chip 
was washed with EDTA for 15 minutes. The EDTA was then removed from the 
secondary port and replaced with a solution of 4% paraformaldehyde (PFA) with 20% 
(v/v) methanol in PBS. The PFA-methanol solution was allowed to wash through the 
chip for 20 minutes to fix the trapped cells. The fixing solution was then replaced 
with distilled water and allowed to wash though the chip for another 15 minutes. 
The  water  was  then  removed  and  replaced  with  Harris’  haematoxylin  solution,  and  
allowed to wash through the chip for 1 to 3 minutes until the nuclei of the cells 
turned blue. This was followed by a 20-minute wash with distilled water. 0.5% 
aqueous eosin-Y solution was then washed through the chip to stain the cytoplasm 
of trapped cells for a further 20 minutes. Finally, distilled water was washed through 
the chip for 20 minutes.  
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3.3.2 ScreenCell Cyto isolation system  
3.3.2.1 Blood processing 
The ScreenCell Cyto CTC isolation system involves the filtration of blood through a 
microporous membrane. A vacuum gradient is applied across the filter using a 
vacutainer. A schematic of the device is shown in figure 3-2. In a falcon tube, 3ml of 
blood was mixed with 4ml of ScreenCell Buffer FC, which contained a formalin 
fixative. The tube was closed, inverted gently to mix, and incubated for 8 minutes at 
room temperature. 7ml of the diluted blood was then transferred to the blood 
reservoir of the Screencell Cyto device. A vacutainer was inserted into the bottom 
module of the device and the blood filtered through the membrane and collected in 
the vacutainer.  When the blood was almost completely filtered, 1.6ml of PBS was 
added to wash the membrane. At the end of the wash, the top and bottom modules 
of the device were disconnected, releasing the microporous membrane filter 
containing the trapped cells. The filter, which is housed within a metal ring, was 
ejected onto a piece of parafilm, with the trapped cells facing up. 
 
3.3.2.2 Haematoxylin and eosin staining 
70μl  of  Harris’   haematoxylin  was  pipetted  directly  onto   the   filter  and   left   at   room  
temperature for 2 minutes. Using forceps, the filter was transferred to a piece of 
filter paper to absorb the excess stain. It was then gently dipped vertically into a 
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reservoir of distilled water, and place on a piece of filter paper to remove excess 
water.  The  filter  was  transferred  once  more  to  parafilm  and  70μl  of  aqueous  eosin-Y 
solution was pipetted onto it and left at room temperature for 30 seconds. Excess 
stain was absorbed by placing on filter paper, before dipping the filter vertically once 
more into a reservoir of distilled water. The filter was then placed on a microscope 
slide and a circular coverslip placed on top, using an aqueous mounting medium.  
 
3.3.3 Histopathalogical assessment and statistical analysis 
After staining, the Clearbridge Biomedics CTChips and ScreenCell Ctyo filters were 
observed under a light microscope by resident pathologists at the Royal Brompton 
Hospital, to assess if they contained any cancer cells. Each chip was classified as 
being positive for cancer cells, negative for cancer cells or containing suspicious cells. 
The assessment was blind and the pathologists were not informed which patients 
the blood samples were taken from. 
To assess the validity of the Clearbridge Biomedics CTChip and ScreenCell Cyto 
devices as diagnostic tools in lung cancer detection, specificity and sensitivity values 
were calculated.  
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Figure 3-3. ScreenCell Cyto device set-up 
Schematic of the operation of the ScreenCell Cyto device. A microporous membrane 
filter is present between the blood reservoir on top and the collection tube 
attachment component on the bottom. Blood is filtered through the microporous 
membrane by a vacuum gradient, applied via the vacutainer. Blood cells, which tend 
to be smaller and more deformable, pass through the gaps, while CTCs, which tend 
to be larger and more rigid, are retained on the surface of the membrane. After 
trapping, identification of isolated cells can be performed by cell staining and 
cytological assessment.104 [Reproduced with permission from the International 
Institute of Anticancer Research.] 
 78 
3.4 Results 
3.4.1 Clearbridge Biomedics: patient demographics and CTChip classification  
Blood was collected from 43 patients and run through the CTChip to capture CTCs. 
Out of the 43 blood samples processed, 7 could not be assessed by the pathologists 
due either to bubbles accidentally being introduced into the chip in the course of the 
run or precipitation of the haematoxylin stain within the chip. A breakdown of the 
patient demographics is given in table 3-1. The mean age of all patients was 66 
years, with a gender ratio of 1:1. Out of the 36 samples that were usable, 25 (70%) 
were from patients with primary lung cancer, 8 (22%) from patients with metastatic 
cancers and 3 (8%) from patients without cancer. Out of the 25 with lung cancer, 14 
(39%) had adenocarcinoma, 6 (17%) had squamous cell carcinoma, 1 (3%) was a 
patient with mixed adenocarcinoma and squamous cell carcinoma and 4 (11%) had 
other primary lung cancers. Of the 33 (92%) patients with cancer, in 12 (36%) the 
tumours were stage I to II, in 20 (61%) the tumours were stage III to IV and 1 (3%) 
could not be staged.  
Pathological assessment   was   performed   blind   to   the   patient’s   cancer   status.   The  
pathologists classified each CTChip into 3 categories, based on their confidence of 
the  presence  of  cancer  cells:   “negative”,  “suspicious”  and  “positive”.  CTChips  were  
classed   as   “negative”   if   no   atypical   cells   were   found,   “suspicious”   if   atypical   cells  
were   found   and   “positive”   if   atypical   cells   distinctly   of   tumour   origin  were   found.  
Examples of each category are shown in figure 3-3. 
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Table 3-1. Patient demographics for Clearbridge study 
VARIABLE VALUE % 
Total sample size 36 100 
Mean age  66 (12) - 
Sex (men) 18 50 
Underlying diagnosis   
Primary lung cancer 25 70 
Adenocarcinoma (ADC) 14 39 
Squamous cell carcinoma (SqCC) 6 17 
Mixed (ADC and SqCC) 1 3 
Other lung carcinomasa 4 11 
Metastatic cancerb 8 22 
No Cancer 3 8 
Tumour grade   
Stage I – II  12 36 
Stage III – IV  20 61 
Unclassified  1 3 
a 1 Small cell carcinoma, 2 large cell neuroendocrine carcinoma, 1 combined large 
cell and small cell carcinoma. b 4 Colorectal carcinoma, 1 renal carcinoma, 1 Hurthle 
cell thyroid carcinoma, 1 chondrosarcoma and 1 leiomyosarcoma.  
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Figure 3-4. Examples of stained CTChips 
A:   Precipitation   of   haematoxylin.   B:   “Negative”   for   cancer   cells.   Numerous   small   cells  
trapped   are   lymphocytes.   C,  G:   “Suspicious”   for   cancer   cells. Cell morphology is not clear 
enough for  a  “positive”  result. D,  E,  F:  “Positive”  for cancer cells. Lightly staining cytoplasmic 
regions are indicated with solid arrows, darkly staining nuclear regions with dotted arrows 
and a prominent nucleolus by a dashed arrow. The width of each crescent-shaped trap is 
20μm. 
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3.4.2 Sensitivity- and specificity-weighted testing scenarios  
Sensitivity, specificity, positive predictive and negative predictive values were 
calculated, for sensitivity-weighted and specificity-weighted tests. These tests were 
carried out at two levels. At the single-tester level, values were calculated for each 
pathologist – CTCs   were   considered   present   in   chips   classified   as   “positive”   or  
“suspicious”   in   sensitivity-weighted analysis, while in specificity-weighted analysis, 
CTCs   were   considered   present   only   in   chips   classified   as   “positive”.   A   tabulated  
representation of this is shown in table 3-2.  
At the two-tester level, values for both pathologists were calculated, with two 
different scenarios corresponding to sensitivity- and specificity-weighted tests. In the 
sensitivity-weighted test scenario, CTCs were considered to be present in the chip as 
long as at least one pathologist says so.  In the specificity-weighted scenario, CTCs 
were considered present only if both pathologists agree. A tabulated representation 
of this is presented in table 3-3. The raw values used for both levels of sensitivity-and 
specificity-weighted analysis are presented in table 3-4.  
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Table 3-2. Single-tester sensitivity- and specificity-weighted analysis 
Are CTCs present? YES NO 
Sensitivity-weighted “positive”  or  “suspicious” “negative”  only 
Specificity-weighted “positive”  only “suspicious”  or  “negative” 
 
 
Table 3-3. Two-tester sensitivity- and specificity-weighted analysis 
Are CTCs present? YES NO 
Sensitivity-weighted at least one pathologist 
says CTCs present 
both pathologists say CTCs 
absent 
Specificity-weighted both pathologists say CTCs 
present 
at least one pathologist 
says CTCs absent 
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Table 3-4. Raw values for sensitivity- and specificity- weighted analysis 
Single-tester analysis 
 Principal pathologist   Second pathologist  
 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
True 
positives 
12 3  10 6 
True 
negatives 
2 3  0 1 
False 
positives 
1 0  1 0 
False 
negatives 
18 27  7 11 
      
 
Two-tester analysis 
 Sensitivity-weighted  Specificity weighted  
 At least 1 pathologist   Both pathologists  
 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
True 
positives 
8 5  6 3 
True 
negatives 
0 1  1 1 
False 
positives 
1 0  0 0 
False 
negatives 
6 9  8 11 
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Table 3-5. Sensitivity and specificity calculations 
Single-tester analysis 
 Principal pathologist   Second pathologist  
% (95% CI) 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
Sensitivity 40 (23 – 59) 10 (2 – 27) 
 
 
*59 (33 – 81) 35 (14 – 62) 
Specificity 67 (12 – 95) *100 (0 – 100) 
 
 
0 (0 – 83) *100 (17 – 100) 
PPV a 92 (64 – 99) *100 (0 – 100) 
 
 
91 (59 – 98) *100 (54 – 100) 
NPV b *10 (2 – 32) *10 (2 – 27) 
 
 
0 (0 – 41) 8 (1 – 39) 
      
 
Two-tester analysis 
 Sensitivity-weighted  Specificity weighted  
 At least 1 pathologist   Both pathologists  
% (95% CI) 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
Sensitivity *57 (12 – 82) 36 (13 – 65) 
 
 
43 (18 – 71) 21 (5 – 51) 
Specificity 0 (0 – 83) *100 (17 – 100) 
 
 
100 (17 – 100) 100 (17 – 100) 
PPV a 89 (52 – 98) *100 (48 – 100) 
 
 
100 (54 – 100) 100 (30 – 100) 
NPV b 0 (0 – 46) 10 (2 – 45) 
 
 
*11 (2 – 48) 8 (1 – 39) 
a Positive predictive value. b Negative predictive value.  
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3.4.3 ScreenCell Cyto patient demographics and filter classification  
Blood was collected from 54 patients in this study and run through the ScreenCell 
Cyto device to capture CTCs. Of the 54 blood samples processed, 3 could not be 
assessed by the pathologists due to the cells drying out following improper mounting 
of the coverslip onto the membrane filter. A breakdown of the patient demographics 
is given in table 3-7. The mean age of all patients was 63 years and 65% were men. 
Of the 51 samples that were usable, 27 (53%) had primary lung cancer, 13 (25%) had 
metastatic cancers, 2 (4%) had other cancers, and 9 (18%) were from patients 
without cancer. Of the 27 with primary lung cancer, 13 (25%) were 
adenocarcinomas, 4 (8%) were squamous cell carcinomas, and 10 (20%) were other 
primary lung cancers. Of the 42 (82%) patients with cancer, 22 (52%) of the tumours 
were stage I to II, 15 (36%) of the tumours were stages III to IV and 5 (12%) could not 
be staged.  
Similar to the conduct of the Clearbridge Biomedics CTChip study, the pathologists 
classified each CTChip into 3 categories, based on their confidence of the presence 
of   cancer   cells:   “negative”,   “suspicious”   and   “positive”   (see figure 3-3). Figure 3-4 
shows some examples of stained filters. Sensitivity, specificity, positive predictive 
and negative predictive values were calculated, for sensitivity-weighted and 
specificity-weighted tests. Sensitivity- and specificity-weighted analysis was 
conducted similar to the Clearbridge Biomedics study described previously (see 
tables 3-2 and 3-3). The raw values used for these calculations are presented in table 
3-8.  
 86 
Table 3-6. Patient demographics for ScreenCell study 
VARIABLE VALUE % 
Total sample size (3 unreadable) 51 100 
Mean age (±SD) 63 (13) - 
Sex (Men) 33 65 
Underlying diagnosis   
Primary lung cancer 27 53 
Adenocarcinoma 13 25 
Squamous cell carcinoma  4 8 
Other lung carcinomas a 10 20 
Metastatic cancer b 13 25 
Other Cancers c 2 4 
No Cancer 9 18 
Tumour grade   
Stage I – II 22 52 
Stage III – IV  15 36 
Unclassified 5 12 
a 5 Carcinoid tumours, 1 adenosquamous carcinoma, 1 small cell lung cancer, 1 large 
cell undifferentiated carcinoma, 1 mixed adenocarcinoma and large cell 
neuroendocrine carcinoma, 1 pleiomorphic carcinoma with adecarcinoma and 
spindle cell carcinoma. b 6 colorectal carcinomas, 2 malignant sarcomas, 1 breast 
carcinoma, 1 melanoma, 1 bladder cancer, 1 pleiomorphic sarcoma, 1 
myxofibrosarcoma. c 1 mesothelioma, 1 chondrosarcoma.  
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Figure 3-5. Examples of stained ScreenCell Cyto filters 
A: No atypical cells. B-E: Atypical cells suspected to be cancer cells indicated by the 
arrows. Cells were stained with haematoxylin and eosin. Scale  bar  represents  20μm.
C 
B A 
D 
E 
 88 
Table 3-7. Raw values for sensitivity- and specificity- weighted analysis 
Single-tester analysis 
 Principal pathologist   Second pathologist  
 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
True 
positives 
20 0  25 1 
True 
negatives 
8 9  8 9 
False 
positives 
1 0  1 0 
False 
negatives 
22 42  17 41 
      
 
Two-tester analysis 
 Sensitivity-weighted  Specificity weighted  
 At least 1 pathologist   Both pathologists  
 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
True 
positives 
28 1  17 0 
True 
negatives 
7 9  9 9 
False 
positives 
2 0  0 0 
False 
negatives 
14 41  25 42 
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Table 3-8. Sensitivity and specificity calculations 
Single-tester analysis 
 Principal pathologist   Second pathologist  
% (95% CI) 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
Sensitivity 48 (32 – 64) 0 (0 – 8) 
 
 
60 (43 – 74) 2 (0 – 13) 
Specificity 89 (52 – 98) 100 (66 – 100) 
 
 
89 (52 – 98) 100 (66 – 100) 
PPV a 95 (76 – 99) - 
 
 
96 (80 – 99) 100 (17 – 100) 
NPV b 27 (12 – 46) 18 (8 – 31) 
 
 
32 (15 – 54) 18 (9 – 31) 
      
 
Two-tester analysis 
 Sensitivity-weighted  Specificity weighted  
 At least 1 pathologist   Both pathologists  
% (95% CI) 
Sensitivity-
weighted 
Specificity-
weighted 
 
Sensitivity-
weighted 
Specificity-
weighted 
Sensitivity 67 (50 – 80) 2 (0 – 13) 
 
 
40 (26 – 57) 0 (0 – 8) 
Specificity 78 (40 – 97) 100 (66 – 100) 
 
 
100 (66 – 100) 100 (66 – 100) 
PPV a 93 (78 – 99) 100 (17 – 100) 
 
 
100 (80 – 100) - 
NPV b 33 (15 – 37) 18 (9 – 31) 
 
 
26 (13 –44) 18 (8 – 31) 
a Positive predictive value. b Negative predictive value. 
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3.4.4 Clearbridge CTChip and ScreenCell Cyto membrane filter: statistical analysis 
Inter-observer agreement with both systems were both 73%; Κ=0.583  ± 0.167 (95% 
CI, 0.256-0.910) for the Clearbridge system and Κ=0.462   ± 0.118 (95% CI, 0.229-
0.694) for the ScreenCell system, indicating that both show moderate agreement, 
according to the Landis and Koch criteria (data shown in table 3-9). 
A sensitivity value of 57% (95% CI, 12-82) was obtained when at least 1 pathologist 
classified a CTChip as containing cancer cells, using a sensitivity-weighted test. This 
was similar to the 59% (95% CI, 33-81) obtained by the second pathologist using a 
sensitivity-weighted test, and higher than the first pathologist’s   sensitivity  value  of  
40% (95% CI, 23-59). Specificity was 100% under all testing conditions, with a 95% 
confidence interval of 17-100 in all testing situations except the principal pathologist 
(100% [95%CI, 0-100]).  
Highest sensitivity values of 67% (95%CI, 50-80) were obtained when at least 1 
pathologist classified a ScreenCell filter as containing cancer cells, using a sensitivity-
weighted test. This was higher than the individual sensitivity values of either 
pathologist, which were 48% (95% CI, 32-64) and 60% (43-74) respectively. 
Specificity was high under all testing conditions, with a value of 100% (95% CI, 66-
100).   
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3.4.5 Comparison of cell preservation and H&E staining  
Cell morphology tented to be better preserved in cells isolated using the ScreenCell 
Cyto device compared to the Clearbridge CTChip. Cells isolated in the CTChip tended 
to exhibit signs of shear stress – the regions of cells close to the edge of the 
crescent-shaped traps could be seen to pull away from the main cell mass. Evidence 
of ruptured cells could also be found in these CTChips (figure 3-6, images A and B). In 
contrast, the ScreenCell Cyto device preserved the morphology of trapped cells 
much more successfully (figure 3-6 images C and D). Hematoxylin and eosin staining 
was also more successful in creating better visual contrast between nuclear and 
cytoplasmic regions in the cells isolated using ScreenCell Cyto compared to the 
Clearbridge CTChip. H&E staining in ScreenCell Cyto more closely approached the 
standard of routine staining of lung tumour sections (figure 3-6 images E and F). 
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Figure 3-6. Comparison of H&E staining between Clearbridge CTChip, ScreenCell 
Cyto and routine histopathological staining of tissue specimens 
Haematoxylin and eosin staining was performed in all of the cell images. H&E 
staining in Clearbridge CTChips (A and B) did not give good visual distinction 
between the nucleus and cytoplasm of cells, compared to routine H&E staining of 
tumour sections (E [NSCLC] and F [SCLC]).105 Comparatively, H&E straining in the 
ScreenCell device (C and D) gave a better contrast between nuclear and cytoplasmic 
regions than staining in the Clearbridge CTChip. [E and F reproduced with permission 
from Elsevier.] 
A 
B 
C 
D 
E 
F 
 93 
3.5 Discussion  
This study managed to achieve my aim of assessing the feasibility of these two 
antibody-independent CTC isolation platforms in lung cancer diagnosis. My second 
aim was to retrieve these isolated CTCs for subsequent molecular analysis, for 
example, characterisation of EpCAM expression. I was unable to succeed in this part 
of the plan, because retrieval of CTCs using the Clearbridge platform proved 
impossible as the retrieval process resulted in very high losses of trapped CTCs. 
While retrieval of CTCs from the ScreenCell device was more easily carried out, 
handling very low cell numbers was difficult with the equipment and expertise I had 
at my disposal. The number of positive or suspicious CTCs picked up in Clearbridge 
was very low, with a maximum count of 3. ScreenCell tended to pick up slightly 
higher numbers, with a maximum count of approximately 10, and also sometimes 
picked up circulating tumour microemboli, which appear as clusters of CTCs on the 
membrane. In order to succeed in CTC retrieval for downstream analyses in the 
future, special procedures would have to be designed to handle low or single cell 
numbers. Alternatively, retrieved cells could be grown in culture to expand cell 
numbers before downstream analyses. These two systems have the benefit of being 
antibody-independent, and thus have the potential to capture a larger 
subpopulation of total CTCs. Granted that CTCs may also be heterogenous for size, 
the development of an antibody-independent CTC retrieval system would be a useful 
addition to current antibody-dependent methods, in order to better study the 
complexities of CTCs.  
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Important aspects in the use of CTC measurement as a diagnostic test for cancer is 
ease of use, time taken and reliability. In this comparative study, ScreenCell was 
found to be far easier to use, requiring very little training to handle and being 
disposable. The Clearbridge, being a microfluidic system, was more complicated to 
operate. For this study, I used the Clearbridge Biomedics CTC0 prototype, which 
required predominantly manual operation. Thus, for the ScreenCell system  the total 
processing time was only minutes. In contrast the Clearbridge system took an 
average to 4 hours to complete. The company has since made advances in 
automating the system, and newer models are much easier to operate. Although this 
has done much to reduce the amount of manual operation needed, the processing 
time is still significantly longer than that for the ScreenCell runs.  
Using the Clearbridge CTChips, it was possible to detect cancer with 57% sensitivity, 
using a sensitivity-weighted testing scenario, where at least one pathologist detects 
CTCs. Using the ScreenCell Cyto filters gave a higher sensitivity of 67% in detecting 
CTCs, using the same testing scenario. Should either of these systems be used 
routinely, the low level of sensitivity would mean that for either, there would still be 
an unacceptably high level of false negatives, as reflected in the low negative 
predictive values of 0% (95% CI, 1-46) and 33% (95% CI, 15-37) for Clearbridge and 
ScreenCell respectively (using a two-tester sensitivity-weighted test).  
In most published studies investigating CTC counts in cancer patients, CTCs are never 
detected in a 100% of all cancer patients tested. The poor sensitivity of the tests 
could be due to a real absence of CTCs from the blood of cancer-patients (making 
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CTCs a poor target for cancer diagnosis). More likely is that there are inherent 
limitations of the CTC isolation procedures resulting in the inability to capture CTCs 
present in the blood.  Shear stress may be a contributing factor to the latter – CTCs 
are subject to high pressures to facilitate filtration in both systems, whether through 
spaces between the traps in the Clearbridge CTChip or through the pores in the 
permeable membrane of ScreenCell Cyto filters. The shear stress due to these 
pressures may have caused the CTCs to lyse during isolation, resulting in a lower 
apparent incidence of CTCs on the stained chips/filters. The shear stress, coupled 
with suboptimal fixing and staining, also often causes the morphology of trapped 
cells to be poor, and difficult to positively identify. This, in turn, makes it challenging 
for the pathologists to confidently detect cancer cells. In order to improve sensitivity, 
staining techniques will have to be improved and further optimised to produce H&E 
results comparable to those obtained during routine cytological and histological 
staining. 
Interestingly, in terms of specificity, both systems had 100% specificity with the two-
tester specificity-weighted tests. This high specificity would mean that the rate of 
false positives is very low, as reflected in the high positive predictive values of 100% 
for both Clearbridge and ScreenCell. The lack of well-preserved cell morphology 
could also be a factor contributing to the high specificity of both tests, as 
pathologists are reluctant to definitively classify an atypical cell as a cancer cell if the 
cells are poorly preserved. This would reduce the rate of false positives and result in 
a high specificity value. It is interesting to note that the 95% confidence intervals for 
specificity were narrower for the Screencell, compared to the Clearbridge, system 
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(66-100 and 17-100 respectively). Cell morphology tended to be better preserved in 
ScreenCell Cyto filters compared to Clearbridge CTChips, and this could be the 
reason for the narrower 95% confidence interval for ScreenCell as compared to 
Clearbridge.   
Together, the data shows that it would not currently be clinically feasible to use 
these tests to diagnose cancer. However, this could change if improvements were 
made to combat the apparent loss of CTCs during processing and to improve the 
preservation of cell morphology. Clearbridge has already taken this step and 
designed a new CTChip with a spiral configuration to minimize the effects of shear 
stress.  
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4 PROTEOLYTIC CLEAVAGE OF EPCAM IN LUNG CANCER:  
4.1 Introduction 
The Epithelial Cell Adhesion Molecule (EpCAM) is a 314 amino acid transmembrane 
glycoprotein expressed in most healthy epithelial tissue, except squamous 
epithelium, where it is absent or present at low levels. In healthy tissue, EpCAM 
expression is limited to the basolateral layer, whereas in carcinomas, expression is 
dispersed across the cell membrane and not confined to the basal layer. In the 
majority of carcinomas, EpCAM is highly upregulated. Adenocarcinomas typically 
exhibit higher EpCAM expression than squamous cell carcinomas. A histological 
assessment conducted in 2006 found high EpCAM expression in 80% of lung 
adenocarcinomas and 54% of squamous cell lung carcinomas. Neuroendocrine and 
large cell lung carcinomas had moderate frequencies of high EpCAM expression of 
64% and 67% respectively.93  
Various different studies have shown that EpCAM plays a role in cancer. Experiments 
by Osta et al. in 2004 showed that breast cancer cell lines knocked down for EpCAM 
expression resulted in a 50% decrease in cell proliferation, as well as more than 90% 
decrease in both cell migration and invasion.106 Munz et al. demonstrated that 
EpCAM transfected HEK293 cells exhibited a decreased dependence on growth 
factors for proliferation as well as increased metabolic activity and colony forming 
potential. In addition, induction of EpCAM expression also induced the expression of 
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c-myc, which is upregulated in a majority of tumours and increases cell proliferation 
by activating the transcription of cell cycle genes, such as cyclins A and E.107  
The EpCAM polypeptide consists of an extracellular domain (EpEX) of 30kDa, a short 
membrane-spanning domain and a small 3kDa intracellular domain (EpICD). The vast 
majority of studies performed thus far have utilized antibodies targeting EpEX to 
measure expression of EpCAM. A recently discovered mechanism for cleavage of 
transmembrane proteins, called regulated intramembrane proteolysis, has revealed 
the role of EpCAM to be more complex than originally thought. In regulated 
intramembrane proteolysis, a transmembrane protein is sequentially cleaved by 2 
intramembrane proteases – a sheddase cleaves the extracellular domain, and an 
intracellular cleavage-inducing protein  (iCLiP) cleaves the intracellular domain. 
EpCAM was found to undergo regulated intramembrane proteolysis, in experiments 
performed in breast and colon cancer cell lines. In regulated intramembrane 
proteolysis of EpCAM, TNF-alpha converting enzyme (TACE) cleaves the extracellular 
domain (EpEX), and this is followed by cleavage of the intracellular domain (EpICD) 
by Presenilin-2 (PS-2). Cleaved EpICD was shown to be present in a transcription 
complex with four and a half LIM domains protein 2 (FHL2) and beta-catenin, which 
translocates into the nucleus and activates transcription of genes of the Wnt/beta-
catenin cell regulatory pathway, one of which is c-myc.96  
Thus far, the study by Ralhan et al. in 2010 is the only one that has demonstrated 
nuclear and cytoplasmic localisation of EpICD in lung cancer, and they did not 
perform localisation studies on normal lung tissue for comparison.108 Proteolytic 
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cleavage of EpCAM has only recently been discovered, and its role in carcinogenesis, 
especially in lung cancer, has not been fully explored. 
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4.2 Hypothesis and aims 
EpCAM proteolysis has only recently been described and the few studies that have 
been conducted have either focused on breast or colon carcinomas, or are broad 
histological studies across the different types of cancers. I hypothesised that EpCAM 
plays a role in pulmonary carcinogenesis by undergoing proteolytic cleavage, 
resulting in the release of its intracellular domain (EpICD), which would then act as a 
nuclear signalling factor that affects regulatory pathways to promote cell 
proliferation, migration and invasion in lung cancer.  
Specific aims: 
To discover whether there is proteolytic cleavage of EpCAM in lung cancer cells. 
If so, does it proceed in a similar manner to that previously described in breast and 
colon cancer cells, or does it involve a mechanism of EpCAM cleavage unique to lung 
cancer?  
If EpCAM cleavage does occur in lung cancer cells, what impact does this have with 
regards to carcinogenic activity of lung cancer cells?  
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4.3 Experimental protocols 
 
4.3.1 EpCAM cleavage in human lung tumour tissue vs PMA-induced cleavage in 
H358 cells 
To analyse EpCAM cleavage in primary lung tissue, matched whole tissue lysates 
were prepared from regions of healthy and tumour tissue obtained from 6 patients 
with suspected lung cancer. Each sample underwent SDS-PAGE and was 
subsequently immunoblotted to detect both the intracellular EpCAM (EpICD) and 
extracellular EpCAM (EpEX). In order to determine whether the resulting banding 
patterns were due to EpCAM cleavage via TACE, in vitro stimulation of TACE activity 
in the adenocarcinoma cell line H358 was conducted, by incubating with a 200nM 
solution of phorbol-12-myristate-13-acetate (PMA), which is a known inducer of 
TACE activity.  
H358 cells were cultured in complete RPMI-1640 medium in 6-well plates until they 
reached approximately 70% confluency. The cells were subsequently serum-starved 
overnight before commencing with the PMA stimulation experiment. After 20 hours 
(the next day) the medium was removed from the culture wells and replaced with 
200nM PMA in serum-free RPMI-1640. A working concentration of 100 to 300nM 
PMA was recommended by the manufacturer and has also been used in other 
published studies of PMA-stimulation of TACE (Doedens, Mahimkar and Black, 2003).  
As the initial PMA stock was solubilised in DMSO, an equivalent volume of DMSO 
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was added to serum-free RPMI-1640 in the wells that were to be tested without 
PMA, to control for vehicle effects. PMA exposure was carried out for 4 hours, at 
37°C in 5% CO2. Cells were then harvested mechanically with a cell scraper and 
whole cell lysates prepared. The samples then underwent SDS-PAGE and were 
immunoblotted with EpEX and EpICD antibodies.  
 
4.3.2 PNGase-F glycosidase assay 
Full-length EpCAM contains 3 predicted N-glycosylation sites. To evaluate if the 
banding patterns observed in the experiments described in 4.3.1 were due to the 
presence of distinct EpCAM cleavage products and not differential glycosylation of 
the same protein, a PNGase-F glycosidase assay was conducted. PNGase-F is an 
enzyme that breaks the glycosidic bond between the proteins and any N-linked 
glycan groups. H358 cells were grown to 70% confluency, serum-starved overnight 
and then stimulated with 200nM PMA in serum-free DMEM for 4 hours. An 
equivalent volume of DMSO was used for PMA-negative conditions, as a vehicle 
control. Whole cell lysates were prepared from these samples, and they were 
incubated with either PNGase-F or the enzyme buffer alone, according to the 
manufacturer’s   protocol,   and   subsequently   underwent   SDS-PAGE and were 
immunoblotted with EpEX and EpICD antibodies.  
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4.3.3 Trypsin incubation assay 
In preparing whole cell lysates for SDS-PAGE, cells were routinely detached from the 
growth surface using a cell-scraper, instead of using incubation with trypsin-edta. As 
EpCAM is a cell surface glycoprotein, enzymatic detachment was avoided to preserve 
the structural integrity of EpCAM for subsequent analysis. However, enzymatic 
detachment via trypsin-EDTA was carried out accidentally in one instance, and 
immunoblots with the resulting cell lysates gave a different banding pattern 
compared to cell lysates derived using a non-enzymatic detachment method. Closer 
analysis of the primary structure of EpCAM revealed the presence of a predicted 
trypsin cleavage site. Subsequently, I conducted a PNGase-F assay on both cell-
scraped and trypsin-edta-detached H358 cells and compared the resulting 
immunoblot patterns. 
 
4.3.4 Inhibition assays 
H358 cells were grown in 6-well plates until 70% confluence in complete RPMI-1640 
medium and subsequently serum-starved overnight before performing the inhibition 
experiment. For this experiment, TAPI-2 was used to inhibit TACE activity, at a 
working concentration of 40PM, and DAPT was used to inhibit PS-2 activity, at a 
working concentration of 10PM. Concentrations were chosen based on the 
manufacturer’s   recommendations   and   from   other   studies   using   these   same  
inhibitors (Yi et al., 2011, Stoyanova et al., 2012). Working solutions for each 
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inhibitor were made up in serum-free RPMI-1640 medium. A PMA time course was 
conducted on the cells as follows: without inhibitors; TAPI-2 alone; DAPT alone; both 
TAPI-2 and DAPT together. A table of the different experimental conditions is 
presented in table 4-1. 
 PMA was added sequentially, to a final working solution of 200nM, starting from the 
24-hour PMA exposure samples and ending with the 1-hour PMA exposure samples. 
For example, PMA was first added to the 24-hour PMA exposure wells, then added 
to the 8-hour PMA exposure wells 16 hours later, the 4-hour PMA exposure wells a 
further 4 hours after, and the 1-hour PMA exposure wells a further 3 hours after, to 
enable cells from all conditions to be harvested at the same time and to reduce 
variation from external sources. As the PMA solution was solubilized and diluted 
using DMSO, when it was added into the 24-hour exposure wells initially, an 
equivalent volume of DMSO was added into the other wells, to control for any effect 
of the vehicle. Cells were incubated at 37°C in 5% CO2. After the assay was complete, 
cells were harvested mechanically and whole cell lysates extracted. The lysates 
underwent SDS-PAGE, and subsequently immunoblotted using EpEX and EpICD 
antibodies.  
 
4.3.5 Treatment with recombinant TACE  
Recombinant TACE (rTACE) was purchased as a lyophilized solid and solubilised in 
sterile, deionized water. rTACE was then diluted in serum-free RPMI-1640 to a 
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working concentration of 100nM (Amour, 1998).  H358 cells were cultured in 
complete RPMI-1640 medium in 6-well plates until they reached 70% confluency. 
The cells were then serum-starved overnight. The next day, H358 cells were 
subjected to four different experimental conditions – no PMA, PMA only, rTACE 
without PMA and rTACE with PMA. All set-ups were incubated for 4 hours at 37°C 
and 5% CO2. Whole cell lysates were then extracted and underwent SDS-PAGE and 
immunoblotting with EpEX antibody. 
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Table 4-1. Experimental  conditions for TACE inhibition assay 
 No inhibitors  
TAPI-2 only 
 
DAPT only 
 
TAPI-2 + 
DAPT 
No PMA 
baseline 
control 
   
PMA 1 hour     
PMA 4 hours     
PMA 8 hours     
PMA 24 hours     
 
 107 
4.4 Results 
 
4.4.1 EpCAM cleavage in primary tissue reveals two distinct EpCAM populations  
Immunoblots of normal lung and lung tumour lysates showed a distinct double-
banding pattern when probed with EpEX antibody. Two EpEX-containing proteins 
were detected, one at 42kDa and one at 37kDa, as shown in figure 4-1. The 42kDa 
protein matches the apparent molecular weight of full-length EpCAM, while the 
37kDa protein could potentially correspond to EpCAM without its EpICD domain. 
Except   for   the   sample   from  patient  2,  who  was  eventually  diagnosed  with  Ewing’s  
sarcoma (bone tumour), the most striking difference between the normal and 
tumour tissue was the marked upregulation of the 37kDa protein in the lung 
tumours. Densitometric readings were obtained for the 42kDa and 37kDa bands for 
the 5 patients with lung cancer. To compare the proportions of EpCAM cleavage 
present between the different patient samples, EpCAM cleavage was expressed as a 
ratio of cleaved EpCAM relative to full-length EpCAM, i.e.  ଷ଻୩ୈୟ  ୤୰ୟ୥୫ୣ୬୲ସଶ୩ୈୟ  ୤୰ୟ୥୫ୣ୬୲. The EpCAM 
cleavage ratios in tumour tissues were normalised against those in the 
corresponding normal tissues. This data is presented in figure 4-2. 
 
EpCAM cleavage increased approximately 9-fold in adenocarcinoma tumours, 2-fold 
in the squamous cell carcinoma tumour and close to 1000-fold in the mixed large cell 
carcinoma and adenocarcinoma tumour, relative to their matched normal tissue. It is 
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important to note that the sample size of this study was very small: n=3 for 
adenocarcinoma, n=1 for squamous cell carcinoma and n=1 for mixed large cell and 
adenocarcinoma. As such, statistical significance testing could not be performed with 
any reliability.  The small sample size in this experiment was due to limitations in the 
amount of fresh tissue that was collected. Approximately 5 tissue samples collected 
early on in the study were used to optimise the tissue lysis protocol, as initial whole 
tissue lysates suffered from low protein concentrations. After optimisation, protein 
concentrations were high enough to perform immunoblots, but volumes remained 
small, especially when tissue samples were smaller than average. Often, there was 
only sufficient material to perform one or two immunoblots. At this juncture, the 
only reasonable conclusion to make was that the 37kDa protein is much more highly 
expressed in the tumour tissue of these five lung cancer patients, compared to their 
normal lung tissue. According to my theory, this suggested that there was more 
EpCAM cleavage occurring in the tumour tissue compared to normal lung tissue. 
While this may be representative of lung cancer in general, further testing is 
required with more samples, across the different lung cancer subsets, in order to 
obtain more robust, informative data.  
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Figure 4-1. Whole cell lysates of primary tissues show different expression levels of 
EpCAM fragments between normal and tumour tissues 
Whole tissue lysates from regions of normal lung tissue and lung tumour tissues 
were prepared from 6 patients (labelled 1-6) suspected to have primary lung cancer. 
Tissues were probed for the presence of EpEX. β-actin was used as a loading control. 
A distinct double-banding pattern was observed, corresponding to 42kDa and 37kDa 
fragments. The most striking difference was the marked upregulation of the 37kDa 
protein in lung tumours compared to their matched normal tissue, with the 
exception of patient 2, which turned out to be a non-lung cancer patient, and patient 
5, who had no detectable EpCAM fragments in the normal tissue. Patients 1, 4 and 5 
were diagnosed with adenocarcinoma, patient 3 with large cell neuroendocrine 
carcinoma and adenocarcinoma, and patient  2  with  Ewing’s  sarcoma. 
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4.4.2 In vitro stimulation of EpCAM cleavage via PMA-induced TACE activation 
suggests a new EpCAM cleavage site 
PMA is a commonly used inducer of TACE activity; I decided to simulate EpCAM 
cleavage in vitro to see if the results matched the data obtained from primary tissue. 
PMA-induced TACE activation of the adenocarcinoma cell line H358 showed the 
same double-banding pattern seen in the tissue immunoblots described in the 
previous section (section 4.4.1, figure 4-1), lending weight to the theory that the two 
bands represent EpCAM and its cleavage product (see figure 4-3). Unexpectedly, the 
37kDa band was detected by both EpEX and EpICD antibodies. This means that both 
bands contain proteins with both EpEX and EpICD domains, disproving the initial 
theory that the 37kDa protein corresponded to EpCAM that had the EpICD portion 
cleaved following proteolysis. From figure 4-3, it can be seen that the 37kDa protein 
was absent without PMA stimulation and only appeared upon activation of TACE via 
PMA, suggesting that the formation of this 37kDa fragment is, nevertheless, TACE-
dependent. Thus, the 37kDa protein is a TACE-dependent EpCAM cleavage product, 
but not the one I originally predicted, as described in the literature for other tumour 
cell types. 
In order to better understand these unexpected results, I took a closer look at the 
primary structure of EpCAM (figure 4-4). This reveals a putative cleavage site within 
EpEX, between arginine80 and arginine81. The EpEX antibody used in this study was 
raised using an immunogenic sequence that overlaps this predicted cleavage site. 
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The immunogenic sequence is as follows, with the predicted cleavage site 
underlined:  
QEECVCENYKLAVNCFVNNNRQCQCTSVGAQNTVICSKLAAKCLVMKAEMNGSKLGRRAKPE
GALQNNDG.  
I then theorised that cleavage of EpCAM at this site could potentially produce a 
cleavage product corresponding to the 37kDa protein. The EpEX antibody still 
retained its capacity to bind to EpEX despite the loss of the EpEX N-terminus, which I 
termed EpN.  
A closer look at the PMA-induced TACE activation immunoblot in figure 4-3, also 
revealed another unexpected outcome. The ratio of the amount of 42kDa to 37kDa 
protein differed, when probed with EpEX and EpICD antibodies. Upon stimulation of 
TACE, EpEX antibody detected a higher proportion of 37kDa protein compared to 
42kDa protein, while the converse was true for the EpICD antibody. Both antibodies 
were probing the same sample, and differential loading would not explain this 
inverse expression pattern. A possible explanation would be that the 37kDa band 
could correspond to 2 distinct proteins – EpCAM without EpN, and EpCAM without 
EpN or EpICD, and there is a possibility that the 37kDa band highlighted by the EpEX 
antibody contains both molecules. Despite a number of attempts to detect free, 
intracellular EpICD, this has proven unsuccessful via immunoblotting, likely due to its 
small size (2-3kDa). It is also possible that because the molecular weight of EpICD is 
so small, resolving and visualising EpCAM cell populations with and without EpICD is 
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difficult using SDS-PAGE. This theory would be consistent with the results in figure 4-
3, where the EpICD antibody is shown to detect less 37kDa protein compared to the 
EpEX antibody. While both 37kDa proteins have lost EpN, a smaller subset of those 
proteins have also lost EpICD, accounting for the lower amount of 37kDa protein 
detected by the EpICD antibody.  
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Figure 4-3. In vitro stimulation of EpCAM cleavage via PMA-induced TACE 
activation produces the characteristic double-banding pattern 
PMA-induced stimulation of TACE resulted in the appearance of a 37kDa fragment, 
containing both EpEX and EpICD, suggesting that the appearance of the 37kDa 
protein is TACE-dependent. However, the ratios of 42kDa to 37kDa fragments were 
not consistent, when probed with EpEX and EpICD antibodies. Immunoblotting using 
EpEX antibodies showed a higher proportion of the 37kDa band relative to the 42kDa 
band, while the converse was true when Immunoblotting using EpICD antibody. The 
37kDa fragment may consist of 2 distinct protein populations, with each protein 
having different affinities to the EpEX and EpICD antibodies.  
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- + 
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Figure 4-4. Primary structure of EpCAM 
Arrow 1 corresponds to the signal peptide for protein modification in the 
endoplasmic reticulum, which is absent in membrane-bound EPCAM. Arrow 2 
corresponds to a putative cleavage site, between 2 arginine residues.109 [Reproduced 
under Creative Commons license.] 
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4.4.3 N-terminal cleavage and not differential glycosylation is responsible for the 
double banding pattern of EpCAM proteins 
As  mentioned  earlier,  analysis  of  the  EpCAM’s  primary  structure  also revealed that 
the cleavage site between arginine80 and arginine81 is a predicted trypsin cleavage 
site. For the majority of the experiments in this thesis, cells were detached from the 
culture surface mechanically using a cell scraper. In this experiment, PMA-stimulated 
H358 cells were incubated with trypsin-EDTA solution at 37°C for 5 minutes or until 
cells detached from the growth surface. Immunoblot analysis of lysates from these 
cells revealed that trypsin incubation resulted in the abolishment of the 42kDa band 
(figure 4-5, lanes 1 and 3).  The proteolytic action of trypsin mimics EpN cleavage 
from full-length EpCAM via TACE, as they both have the same predicted cleavage site 
and result in formation of a 37kDa band.  
To further confirm that the double-banding pattern observed is due to EpN cleavage 
and not the result of differential glycosylation of EpCAM, a PNGase-F assay (to 
remove glycosol side chains) was performed on lysates of H358 cells that had been 
incubated with PMA to activate TACE activity. If the two bands were the result of 
differentially glycosylated EpCAM, a single band would be expected upon incubation 
with PNGase-F, corresponding to full-length, unglycosylated EpCAM. Instead, 
PNGase F activity caused a downward shift in both the 42kDa and 37kDa bands, 
suggesting that the two bands are not differentially glycosylated versions of full-
length EpCAM (figure 4-5). 
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Figure 4-5. Detection of differentially glycosylated EpCAM products  
H358 cells were incubated with PMA to induce TACE activity and EpCAM cleavage for 
this assay. Treatment of the cells with trypsin resulted in the abolishment of the 
higher molecular weight bands, mimicking cleavage of EpN. Incubation of lysates of 
PMA-stimulated H358 cells with PNGase F caused the downward shift of both the 
42kDa and 37kDa bands, suggesting that difference in size between the bands is not 
due to differing glycosylation patterns.  
- + 
- 40kDa 
- 30kDa 
EpEX 
- + PNGase F 
- - + + Trypsin 
 118 
4.4.4 EpN cleavage from full-length EpCAM is TACE-dependent, while EpICD 
cleavage is PS-2-dependent 
To investigate which of the two enzymes implicated in regulated intramembrane 
proteolysis of EpCAM was responsible for EpN cleavage, an inhibition assay was 
performed. In PMA-stimulated H358 cells, TAPI-2 was used to inhibit TACE activity 
and DAPT was used to inhibit PS-2 activity. H358 cells were stimulated with PMA for 
1, 4, 8, and 24 hours, under the following conditions:  without inhibitors; addition of 
TAPI-2 only; addition of DAPT only; addition of both TAPI-2 and DAPT together. 
Protein expression levels for each experimental condition were measured against a 
baseline control condition, comprising of H358 cells that were not stimulated with 
PMA.  
This experiment was repeated three times, and a representative immunoblot of 
these samples with EpEX and EpICD antibodies is presented in figure 4-6, showing 
the double-banding pattern observed in previous experiments. Notably, while 
expression profiles of the 42kDa protein were similar when probed with either EpEX 
or EpICD antibodies, as expected, there were differences in the expression profiles of 
the 37kDa protein detected by these antibodies. This is consistent with the theory 
that the 42kDa protein corresponds to full length EpCAM, while the 37kDa protein 
represents two EpCAM subpopulations: EpCAM without EpN, which can be detected 
by antibody to EpICD, and EpCAM without either EpN or EpICD, which cannot be 
detected by EpICD. 
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To compare changes in EpN cleavage, ratios of EpN-cleaved EpCAM to full-length 
EpCAM were calculated (i.e. ଷ଻୩ୈୟ  ୤୰ୟ୥୫ୣ୬୲ସଶ୩ୈୟ  ୤୰ୟ୥୫ୣ୬୲) for each condition and compared to the 
baseline control. The results are presented in figure 4-7. In the absence of inhibitors, 
EpN cleavage peaked at 4 hours of PMA exposure, showing a 1.7-fold increase 
relative to baseline, dropping to a 1.3-fold increase at 8 hours and returning to 
baseline levels by 24 hours. The levels of EpN cleavage at 4 and 8 hours of PMA 
exposure were significantly higher compared to baseline levels (p=0.008 and 0.009 
respectively). A similar pattern was observed during PS-2 inhibition by DAPT. EpN 
cleavage showed a 2-fold increase at 4 hours of PMA exposure, a 1.8-fold increase at 
8 hours, and a 1.6-fold increase at 24 hours (p=0.004, 0.01 and 0.005 respectively). 
When TACE is inhibited by TAPI-2, both with or without DAPT, no significant changes 
in EpN cleavage were observed. These results show that inhibition of TACE via TAPI-2 
resulted in inhibition of EpN cleavage, but inhibition of PS-2 via DAPT did not. This 
suggests that EpN cleavage from full-length EpCAM occurs in a TACE-dependent and 
PS-2-independent manner.  
In addition to EpN cleavage, differences in EpICD cleavage were observed in the 
inhibition experiment. The 37kDa band corresponds to both (1) EPCAM without EpN 
and (2) EpCAM without either EpN or EpICD. The former would be detected by both 
EpEX and EpICD antibodies, while the latter would only be detected by EpEX, and 
this difference is reflected in the immunoblot in figure 4-6. As a brief example: at 4 
hours of PMA exposure in the presence of both inhibitors, the 37kDa fragment was 
detected by the EpEX antibody but not the EpICD antibody. At 4 hours of PMA 
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exposure in the absence of either inhibitor, the 37kDa fragment was detected by 
both antibodies. However, at 4 hours of PMA exposure in the presence of TAPI-2, the 
37kDa fragment was only detected by EpEX, suggesting that TACE inhibition results 
in the loss of the EpICD domain from the EpN-cleaved EpCAM fragment. 
Similar to ratios of EpN cleavage mentioned previously, ratios of EpICD retention 
were calculated, to enable more quantitative comparisons between the different 
conditions. EpN-cleaved EpCAM with EpICD present was expressed as a fraction of 
total EpN-cleaved protein, i.e. ଷ଻୩ୈୟ  ୠୟ୬ୢ  ୢୣ୲ୣୡ୲ୣୢ  ୠ୷  ୉୮୍େୈ  ୟ୬୲୧ୠ୭ୢ୷  ଷ଻୩ୈୟ  ୠୟ୬ୢ  ୢୣ୲ୣୡ୲ୣୢ  ୠ୷  ୉୮୉ଡ଼  ୟ୬୲୧ୠ୭ୢ୷ . Values were 
normalised against the baseline control, and the results are presented in figure 4-8. 
In the absence of either inhibitor, no significant changes in EpICD retention were 
observed with increasing durations of PMA exposure. The presence of TAPI-2 also 
produced similar results. In the presence of the PS-2 inhibitor DAPT, however, 
significant increases in EpICD retention were observed at 4, 8, and 24 hours of PMA 
exposure. EpICD retention increased 1.3-fold at 4 hours, 1.5-fold at 8 hours and 1.8-
fold at 24 hours (p=0.02, 0.005 and 0.0003 respectively. This pattern of EpICD 
retention was also seen when both inhibitors were present. In the presence of both 
DAPT and TAPI-2, EpICD retention increased 1.7-fold at 1 hour of PMA exposure, 1.4-
fold at 4 hours, 1.4-fold at 8 hours and 1.5-fold at 24 hours (p=0.002, 0.02, 0.02 and 
0.003 respectively). Together, these results suggest inhibiting PS-2, but not TACE, 
causes increased EpICD retention and inhibits EpICD cleavage. Therefore, EpICD is 
cleaved from EpCAM in a PS-2-dependent manner. 
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I used ratios (and ratios of ratios) in these analyses as a tool to (semi-)quantify my 
immunoblot data, in order to perform statistical testing. It should be noted however, 
that this is not without its pitfalls. Errors can occur, especially when differences 
between numerators and denominators are large. My analyses did not involve many 
data extremes and this should not have a big effect on the interpretation of my 
results.  
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    Figure 4-6. H358 cells w
ere stim
ulated w
ith PM
A (0-24 hours) in the presence and absence of TACE and PS-2 inhibitors. Im
m
unoblotting 
revealed EpN
 cleavage to be TACE-dependent. 
 O
n exam
ination of the im
m
unoblot, EpN
 appears to be TACE-dependent. The m
ost obvious exam
ple of this can be seen w
hen looking at 
differences in expression levels at the 4h interval com
pared to baseline (0h). In the absence of both TACE and PS-2 inhibition (TAPI-2-, DAPT-), 
EpN
 cleavage (resulting in accum
ulation of the 37kDa fragm
ent) w
as significantly increased com
pared to the baseline control (p=0.008). A 
sim
ilar upregulation in the 37kDa fragm
ent can be observed w
hen PS-2 is inhibited (DAPT+), suggesting that EpN
 cleavage is PS-2-
independent. W
hen TACE is inhibited (TAPI-2+), EpN
 cleavage is dam
pened, suggesting that it is TACE-dependent. The expression levels of the 
37kDa fragm
ent also appeared to differ w
hen probed w
ith either EpEX or EpICD antibodies. This observation w
as analysed m
ore quantitatively 
in figure 4-8.  
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Figure 4-7. Effect of inhibitors of TACE and PS-2 on the ratio of EpN cleaved to 
uncleaved EpCAM.  
EpN cleavage was compared in the presence and absence of inhibitors of TACE and 
PS-2 by calculating the ratios of 37kDa:42kDa protein levels, i.e. ୉୮େ୅୑  ୵୧୲୦୭୳୲  ୉୮୒୤୳୪୪ି୪ୣ୬୥୲୦  ୉୮େ୅୑    
under all conditions. In the absence of inhibitors, EpN cleavage was significantly 
higher at 4 and 8 hours of PMA exposure (p=0.008, 0.009 respectively). A similar 
pattern was also observed in the presence of PS-2 inhibitor DAPT (p=004, 0.01, 0.005 
at 4, 8 and 24 hours respectively). TACE inhibition via TAPI-2 abolished this increase 
in EpN cleavage, both with and without DAPT, so that no significant changes in EpN 
cleavage was observed, indicating a role for TACE in this process.
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Figure 4-8. Effect of inhibitors of TACE and PS-2 on EpICD retention in EpN-cleaved 
EpCAM. 
 
 
EpICD retention was compared between conditions by calculating the ratios of EpN-
cleaved EpCAM with EpICD to total EpN-cleaved EpCAM, 
i.e.   ଷ଻୩ୈୟ  ୠୟ୬ୢ  ୢୣ୲ୣୡ୲ୣୢ  ୠ୷  ୉୮୍େୈ  ୟ୬୲୧ୠ୭ୢ୷  ଷ଻୩ୈୟ  ୠୟ୬ୢ  ୢୣ୲ୣୡ୲ୣୢ  ୠ୷  ୉୮୉ଡ଼  ୟ୬୲୧ୠ୭ୢ୷ .  No significant changes in EpICD retention 
were observed in the absence of inhibitors or in the presence of TAPI-2. In the 
presence of the PS-2 inhibitor DAPT, EpICD was retained at significantly higher levels 
at 4, 8, and 24 hours of PMA exposure (p=0.02, 0.005 and 0.0003 respectively). 
EpICD retention was also similarly higher when both inhibitors were present 
(p=0.002 0.02, 0.02 and 0.003 at 1, 4, 8, and 24 hours of PMA exposure respectively) 
suggesting PS-2 is responsible for EpICD cleavage. 
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Recombinant TACE (rTACE) was commercially available, and I decided to determine 
whether treatment of H359 cells with rTACE would stimulate EpN. The results of this 
experiment are shown in figure 4-9. In the absence of stimulation with PMA, EpN 
cleavage did not occur and the 37kDa band was absent. This was true even when 
rTACE was applied to the cells. This suggests that these H358 cells do not undergo 
baseline endogenous EpN cleavage. Exposure of the cells to PMA induced EpN 
cleavage, resulting in the appearance of the 37kDa band. Interestingly, applying 
rTACE to PMA-exposed cells resulted in greater conversion of the 42kDa band to 
37kDa band. In order to quantify this result and test for significance, I expressed EpN 
cleavage as the ratio of EpN-cleaved EpCAM to full length EpCAM (ଷ଻୩ୈୟ  ୠୟ୬ୢସଶ୩ୈୟ  ୠୟ୬ୢ). The 
addition of rTACE to PMA-stimulated cells resulted in a significant, 1.4-fold increase 
in EpN cleavage (p=0.02). This confirms that EpN is cleaved from full-length EpCAM 
in a TACE-dependent manner.  
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Figure 4-9. Effect of recombinant TACE on EpN cleavage from EpCAM 
A double banding pattern was only observed upon PMA stimulation, even in the 
presence of rTACE. Adding rTACE to PMA-stimulated cells caused a decrease in the 
42kDa band and an increase in the 37kDa band. This is analogous to EpN cleavage, 
which is expressed as the ratio of the 37kDa band to the 42kDa band. The graph 
shows a 1.4-fold increase in EpN cleavage when rTACE was added to PMA-stimulated 
cells, once again suggesting that EpN cleavage is TACE-dependent. 
PMA - + + - 
rTACE - + - + 
EpEX 
β -tubulin 
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4.4.5 Expression of EpCAM protein in normal lung tissue  
In order to visualise the pattern of EpCAM expression in human lung tissue, FPPE 
sections of normal lung and lung tumour tissue were immunofluorescently stained 
with EpCAM antibodies. Prior to the discovery of EpCAM cleavage to EpN, my initial 
aim was to fluorescently label EpEX and EpICD domains within the lung tissue, using 
EpEX and EpICD primary antibodies as well as fluorescently labelled secondary 
antibodies. I first performed double-staining using EpEX (red) and EpICD (green) 
antibodies, together with DAPI (blue) as a nuclear stain, to label FFPE sections of 
normal and tumour lung tissue from a patient with adenocarcinoma.  
Figure 4-10 illustrates the finding that there is minimal EpEX or EpICD expression in 
the majority of normal alveolar epithelial cells (image A). However, a small number 
of cuboidal cells located in the alveolar wall showed expression of EpCAM at the 
plasma membrane. In figure 4-10 (B and D), an orange-yellow outline can be seen in 
these cells (indicated by the solid arrows), caused by the co-localisation of EpEX and 
EpICD. EpCAM appears to be localised around the whole cell, instead of being limited 
to the basolateral membrane as the literature suggests. However, this is proabably a 
consequence of the cross section of the tissue slicing. Free intracellular EpICD 
(green) was not observed in these cells. In other cells, cytoplasmic EpICD was 
observed, in the absence of membranous EpEX and EpICD (indicated by the dotted 
arrows). The airway wall cells in which EpICD cleavage was detected were thinner 
and more elongated than the cells with membranous EpCAM. Nuclear localisation of 
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EpICD was not observed in normal lung cells. The cuboidal cells and the thinner, 
more elongated cells most likely correspond to type II and type I alveolar epithelial 
cells, respectively. Type I cells line the majority of the alveolar surface (>90%) and 
facilitate gas exchange, while type II cells regulate the alveolar environment by 
releasing pulmonary surfactant to prevent alveolar collapse at low surface tension 
during expiration. They also release surfactant-associated proteins (SPA and SPD) 
and other proteins that are important in immune defence, repair and maintenance 
of pulmonary homeostasis (described in the introduction). Thus, the type 1 and 2 
epithelial cells have very different specialised roles and it is perhaps not surprising 
that they show different patterns of EpCAM. EpICD and EpEX localisation. 
Interestingly, a few larger cells in the alveolar space of the normal lung tissue were 
observed to contain intracellular EpICD (figure 4-10C). These cells are most likely 
alveolar macrophages, being larger than the cuboidal epithelial cells with the 
commonly observed off-centre nucleus. EpCAM expression is thought to be limited 
mainly to epithelial cells, and macrophages would not be expected to express 
EpCAM endogenously. One hypothesis is that the EpICD detected in these 
macrophages was the result of efferocytosis of abraded EpICD-containing type 1 
epithelial cells. Interestingly, only EpICD, and not EpEX, was observed within these 
macrophages. It is unlikely in normal lung that the type 2 cells would die and be 
sloughed off and efferocytosed by macrophages as they are the progenitor cells of 
type 1 cells and are not terminally differentiated, which may explain why there was 
no EpCAM in the macrophages. Furthermore selective efferocytosis of type I cells 
containing EpICD but no membrane bound EpEX may be because loss of membrane-
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bound EpEX is a signal for macrophages to clear faulty, dying or potentially 
oncogenic type I cells. This seems unlikely, however, as the majority of the type I 
cells observed in the section did not express EpCAM at all. Another possibility would 
be that these EpICD-containing cells are newly differentiated type 1 cells. EpCAM 
cleavage may occur during differentiation of type 2 cells into type 1 cells, and some 
faulty, newly-differentiated type 1 cells may undergo efferocytosis by alveolar 
macrophages.  
The presence of cytoplasmic EpICD in these macrophages is also unexpected as 
EpICD is a very small protein (2 to 3 kDa) and would be quickly degraded by 
proteolytic enzymes in the efferosomes. It is unknown whether EpICD is present in 
the macrophage efferosome or free in the cytoplasm of these macrophages. If the 
latter is the case, could the nuclear signalling capacity of EpICD have a role in 
macrophages? Studies of EpCAM cleavage in healthy lung epithelia and 
macrophages have not been published and further research in this area would be 
needed to address these questions.  
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Figure 
4-10. 
EpEX 
and 
EpICD 
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m
unofluorescence 
in 
an 
FFPE 
section 
of 
norm
al lung 
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uclear stain, blue; EpICD, green; EpEX, red.]  
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num
ber of cuboidal cells (solid arrow
s B, D), EpEX 
and EpICD colocalised at the plasm
a m
em
brane. 
These 
likely 
correspond 
to 
type 
II 
alveolar 
epithelial cells. Free cytoplasm
ic EpICD w
as not 
observed in these cells. In a num
ber of elongated 
cells, (dotted arrow
s B, D) free cytoplasm
ic EpICD 
w
as observed, but no EpEX expression. These 
likely correspond to type I alveolar epithelial cells. 
A num
ber of larger cells in the alveolar space 
w
ere observed to contain free cytoplasm
ic EpICD 
(C). These are likely to be m
acrophages, w
hich 
have efferocytosed type I alveolar epithelial cells. 
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4.4.6 Detection of EpICD but not EpN cleavage in adenocarcinoma  
In an FFPE section of a pulmonary adenocarcinoma, EpCAM expression was 
markedly higher in the cancer cells compared to normal cells. Adenocarcinoma cells 
are characterised by their glandular formation around a central lumen. Figure 4-11 
image A, shows that adenocarcinoma cells express much higher levels of EpEX and 
EpICD compared to surrounding tissue, which resembled the normal lung epithelial 
tissue described in the previous section. Membranous EpEX tended to be co-
localised with EpICD, seen in the yellow regions outlining most of the cancer cells 
(see also figure 4-12). Membrane-bound EpEX was present in the majority of the 
adenocarcinoma cells, at varying levels and distribution around the cell. EpEX 
expression tended to be higher at zones of cell-cell contact (4-11C, indicated by 
arrows). This is consistent with evidence in the literature that EpCAM is located close 
to and interacts with claudin to regulate tight junction adhesions and E-cadherin to 
modulate adherens junction adhesions.90-92  
Aside from the plasma membrane, EpICD was also observed intracellularly. 
Disappointingly, no EpICD was detected in the cell nuclei. A significant amount of, 
blue and green fluorescence was often detected interspersed together (figure 4-12, 
panel C), possibly reflecting that the nucleus of a cell is not solid or evenly smooth 
and as a result, regions within the nuclear region of a slide section may actually 
correspond to cytoplasmic space. Consequently, the only way to determine if EpICD 
is present inside the nucleus is if it co-localises with the blue DAPI stain. This would 
result in a tell-tale cyan colour, which was not observed.   
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Following the discovery of EpN cleavage in lung cancer, I performed 3-antibody 
immunofluorescence staining for EpEX (red), EpICD (green) and EpN (blue), using 
TRO-PRO-3-iodide (magenta) as a nuclear stain (figure 4.13). Compared to normal 
tissue (A), the adenocarcinoma tissue (B-D) showed greater expression levels of 
EpCAM. Co-localisation of EpEX, EpICD and EpN at the cell membrane was observed 
in the adenocarcinoma cells (white cell outlines in B-D), at varying levels within 
different regions of adenocarcinoma cells. As with the 2-antibody staining described 
earlier, membranous expression of full-length EpCAM (containing EpEX, EpICD and 
EpN) tended to occur at higher levels at regions of cell-cell contact. The 
adenocarcinoma cells, arranged in a typical glandular formation, showed almost no 
membranous expression at regions facing the central lumen, which is a zone of no 
cell-cell contact (figure 4-13, C). This is once again consistent with the literature 
suggesting that EpCAM is expressed near tight junctions and in adherens junctions 
between cells.   
EpEX and EpN were always observed to co-localise together, as seen in figures 4-14 
and 4-15 (images b, c and e). The absence of areas expressing EpEX but not EpN 
suggests that there was no EpN cleavage in this adenocarcinoma, contrary to what 
was expected from earlier immunoblotting experiments (sections 4.4.1 to 4.4.3). In 
addition to its presence in the plasma membrane (in full-length EpCAM), EpICD was 
also observed in the cytoplasm of adenocarcinoma cells, suggesting that EpICD 
cleavage occurred in these cells (figures 4-14 and 4-15, images a and e).  
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Figure 4-11. Co-localisation of EpEX and 
EpICD im
m
unofluorescence in a lung 
adenocarcinom
a FFPE section 
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uclear stain, blue; EpICD, green; EpEX, 
red.] 
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 Figure 4-12. Localisation of EpEX 
and 
EpICD 
im
m
unofluorescence 
alone 
and 
together 
in 
the 
sections in figure 4-11B and C 
[N
uclear stain, blue; EpICD, green; 
EpEX, red.] EpEX and EpICD w
ere 
observed to colocalise at the cell 
m
em
brane 
(1B-3B). 
EpICD 
w
as 
also detected in the cytoplasm
 of 
the 
cell 
(1C). 
EpICD 
w
as 
not 
detected in the nuclei of the cells 
(1C, 3C). The telltale cyan-w
hite 
colour show
ing colocalisation of 
EpICD (green) w
ithin the nucleus 
(DAPI, blue) w
as absent. 
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Figure 
4-13. 
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4.4.7 Two morphologically indistinguishable sub-populations were detected in a 
squamous cell carcinoma section with differing patterns of EpICD and EpN 
cleavage 
Triple-antibody immunofluorescence staining in a section of squamous cell 
carcinoma showed a different pattern of EpCAM localisation. Characteristically, 
squamous cell carcinomas are stratified cells, with a higher cytoplasm to nucleus 
ratio compared to adenocarcinoma cells (figure 4-16). Cells were arranged in two 
distinct compartments in this tumour section. The two compartments are shown 
separated by the dashed line in figure 4-18, and henceforth referred to as 
compartment X and compartment Y.  
Cells in both compartments showed intracellular EpICD localisation (figures 4-16 and 
4-17, images a and d). EpICD also appeared to be localised to the plasma membrane 
of cells in compartment X but not in Y. This is visualised as the orange-yellow cell 
outlines caused by co-localisation of EpICD and membrane-bound EpEX in 
compartment X cells (figure 4-17, image d).  
Compartment Y contained 2 different cell types: elongated spindle-like cells and cells 
that were more cuboidal. EpEX was observed in the cuboidal cells in compartment Y, 
which made up about 50% of all compartment Y cells. EpEX appeared not to be 
membrane-delimited in these cuboidal cells and was observed in the cell cytoplasm, 
with cytoplasmic EpICD (figure 4-17, image b). The spindle cells in compartment Y 
only expressed cytoplasmic EpICD, and did not appear to show EpICD expression at 
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the membrane or EpEX expression anywhere within the cells. Cells in compartment X 
and Y also differed in their presence of EpN. Figure 4-17 (image e), shows EpN co-
localised with EpEX at the cell membranes of cells in compartment X, resulting in 
magenta cell outlines. The cuboidal cells in compartment Y had outlines that showed 
up slightly pink, but were noticeably redder in colour (i.e. less blue), suggesting that 
EpN cleavage has occurred in these cells.  
These observations suggest that different patterns of EpCAM cleavage occur in each 
cell type. Cells in compartment X had full-length EpCAM at the cell membrane, but 
also underwent EpICD cleavage. EpICD cleavage was also observed in the spindle-like 
cells in compartment Y, but possibly to a greater degree of completion, as EpICD was 
no longer detected in the cell membrane. One possible explanation for this result 
could be that the cells in compartment X have retained epithelial characteristics, 
while the spindle-like cells in compartment Y have undergone epithelial to 
mesenchymal transition (EMT). Loss of surface expression of EpCAM, as observed in 
these spindle cells, is an indicator of EMT.110,111 Disappointingly, and contrary to the 
hypothesis, nuclear localisation of EpICD was not seen in any of the cell types. 
In addition to the cell membrane, EpEX was also detected in the cytoplasm of 
compartment Y cuboidal cells. Of note, while intracellular EpICD did not always co-
localise with intracellular EpEX, intracellular EpEX always co-localised with EpICD; 
from figure 4-17 image d, green regions indicating free EpICD appear in these cells 
but no red regions. Only orange regions appear, indicating colocalisation of EpICD 
and EpEX. This suggets that free EpICD exists in the cytoplasm but cytoplasmic EpEX 
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always exists together with EpICD. Taking EpN cleavage in these cells into account, 
cytoplasmic EpEX likely exists as part of full-length or EpN-cleaved EpCAM. The 
presence of intracellular EpEX in cancer cells has been described in published 
reports, but the exact mechanisms that cause this are unknown.99,112 The total 
amount of EpEX detected in the compartment Y cuboidal cells was noticeably more 
obvious than in compartment X cells, and it is possible that the EpEX antibody could 
be detecting newly synthesized and processed EpCAM en route to the cell surface. 
However, EpN cleavage was detected in these cells, making this theory questionable.  
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4.5 Discussion 
This study provides the first evidence for occurrence of EpCAM cleavage in lung 
cancer. However, the cleavage process has proven to be more complex than 
previously thought. While my initial aim was to discover if EpCAM cleavage, 
particularly EpICD cleavage, occurs in lung cancer, my experiments were initially 
hampered by the inability to detect free intracellular EpICD on immunoblots, due to 
its small size. To get around this problem, I decided to analyse the characteristic 
double banding pattern more closely, to infer EpICD cleavage based on the presence 
of bands that were detected by EpEX antibodies but not by EpICD antibodies. It was 
precisely because of this that EpN cleavage was discovered in my immunoblotting 
experiments, and this study reports this previously undescribed EpN cleavage from 
EpCAM for the first time. Inhibition experiments performed found that EpN cleavage 
occurs via a TACE-dependent mechanism, while EpICD cleavage occurs via a PS-2 
dependent mechanism.  
Published reports in breast and colon carcinoma cell lines suggest that EpCAM 
cleavage proceeds in a sequential manner, i.e. EpEX cleavage occurs before EpICD 
cleavage. However, my experiments did not detect any EpCAM fragments that 
contained EpICD but not EpEX. EpEX is a very large domain, and makes up 265 out of 
the 314 amino acids in the full-length EpCAM protein.  It is therefor possible that my 
immunoblot experiments did not detect EpEX cleaved EpCAM due to the small size 
of the remaining EpCAM fragment, which would have a predicted molecular weight 
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of approximately 5 to 6 kDa. However, I did detect EpCAM fragments that contained 
the EpEX domain but not the EpICD domain in many of my immunoblot experiments 
in this chapter, challenging the notion that EpCAM cleavage occurs in a step-wise 
manner, beginning with EpEX cleavage.  
In order to shed more light on EpEX cleavage in lung cancer, which has not been 
described much in this study so far, there would need to be a way to overcome this 
inability to detect the remaining EpEX-cleaved EpCAM fragment (containing EpICD 
and the transmembrane domain), which is too small to be detected on immunoblots 
at present. A possible solution to this would be to transfect a low or non-EpCAM 
expressing lung cancer cell line with a plasmid containing an EpCAM C-terminal-
fusion protein construct. This would C-terminally tag EpCAM at the EpICD domain, 
increasing its size and allowing it to be detected on an immunoblot. I have started 
work on transfecting the low EpCAM-expressing lung adenocarcinoma cell line A549 
with an plasmid containing an EpCAM-GFP construct, but did not manage to 
complete this work in time for inclusion in this thesis (see appendices, sections 7.1 
and 7.2 under ongoing work). 
From immunofluorescence work in this study, minimal EpCAM expression was 
observed in the majority of healthy lung cells. However, some of the more elongated 
cells that made up the majority of the lung epithelium, likely to be alveolar type I 
cells, were shown to express intracellular EpICD, but not EpEX. Co-localisation of 
EpEX and EpICD at the cell membrane was observed also in a few cuboidal cells, 
likely to be alveolar type II epithelial cells. This difference in EpCAM expression 
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between alveolar type I and II cells has not been described before and nothing is 
known about its significance. Additionally, a few alveolar macrophages were seen to 
contain EpICD, but no EpEX.. This suggests that these macrophages may be taking up 
EpICD-expressing type I cells via efferocytosis. Only a fraction of the alveolar type I 
cells appeared to express intracellular EpICD and it is unknown how these cells differ 
from other type I cells. They could potentially be faulty cells or newly differentiated 
cells. Investigating this could shed some light on whether EpCAM cleavage plays a 
role as a signal for efferocytosis by macrophages. If so, this may have important 
implications and applications for EpCAM targeted therapy in lung cancer.  
EpCAM expression was seen to be markedly higher in adenocarcinoma cells 
compared to healthy cells and co-localisation of membranous EpEX and EpICD was 
observed. EpICD was also observed in the cytoplasmic space of most cells, but 
contrary to my hypothesis, no nuclear EpICD was observed. Disappointingly, staining 
for EpN did not reveal any cleavage in the adenocarcinoma section.  
In a squamous cell carcinoma section, cells appeared to be separated into two 
distinct compartments, which I referred to as compartment X and Y. Compartment X 
contained cells that had membranous EpEX and EpICD expression and some 
cytoplasmic EpICD. Again, no nuclear EpICD was observed. Compartment Y 
contained two cell types. Both cell types did not show membrane EpEX or EpICD 
localisation, but the cuboidal cells expressed cytoplasmic EpEX and EpICD, while the 
spindle-like cells only expressed cytoplasmic EpICD. Additionally EpN cleavage was 
observed in the cuboidal cells, in the cells in compartment X. The differences in 
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EpEX, EpICD and EpN localisation between these different cell types reflect a 
complex process of EpCAM cleavage. The spindle-like cells are likely to be tumour 
associated fibroblasts or possibly a subset of tumour cells that have acquired 
mesenchymal characteristics. The cuboidal cell type could represent an intermediate 
stage between the epithelial tumour cells in compartment X and the mesenchymal 
spindle-like cells. Perhaps the loss of cell adhesion upon escape from compartment X 
could have been one of the triggers for the EMT event. Future work in testing this 
hypothesis would require molecular characterisation of these cell subtypes with 
epithelial and mesenchymal markers.  
It is important to note that tissue specimens from only 3 patients were used for 
immunofluorescence staining in this study – 2 from patients with adenocarcinoma 
and one from a patient with squamous cell carcinoma. Tissue sections from a larger 
number of patients would need to be analysed in the future, in order to see if the 
patterns observed here are representative of these two lung cancer subtypes. 
In conclusion, this study describes the first evidence of EpCAM cleavage in lung 
cancer. While the process has proved to be more complex than originally thought, 
the discoveries in this study open up many more avenues for future research into 
this poorly understood field.  
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5 SUMMARY DISCUSSION AND FUTURE WORK 
This study was divided into two areas: an investigation of the feasibility of lung 
cancer diagnosis via EpCAM-independent CTC detection and a study of the 
mechanisms of EpCAM cleavage in tumorigenesis and progression in lung cancer. 
Conventionally, lung cancer diagnosis is carried out via histopathological assessment 
of biopsied material from suspected tumour tissue, retrieved using a number of 
different techniques. Most of these techniques are quite invasive, ranging from 
fibreoptic bronchoschopies to surgical resections. As such, my hypothesis was that 
CTC detection could be a possible route to devising a non-invasive diagnostic test for 
cancer. The two CTC isolation platforms tested in this study, however, suffered from 
low sensitivity values, in the range of 57% to 67%. To put this in the context of 
current routine clinical diagnostic techniques, the sensitivity values of flexible 
bronchoscopy and transthoracic needle aspiration for tissue biopsy are 88% and 90% 
respectively.113 Notably, sputum cytology has a sensitivity value of 66%, similar to 
the sensitivity value obtained using ScreenCell Cyto.113 Like the ScreenCell Cyto 
system, sputum cytology is also a non-invasive procedure, and has the added benefit 
of not requiring special equipment. Because of its relatively low sensitivity value, 
however, sputum cytology is almost always followed by another clinical diagnostic 
test to confirm the presence of lung cancer. Similarly, the use of ScreenCell Cyto 
alone would not be sufficient to confidently diagnose lung cancer.  
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These tests have potential but are not ready for use in lung cancer diagnosis at this 
stage. However, while sensitivity values were low, specificity values for both CTC 
isolation platforms were 100%, suggesting these systems of CTC-isolation for lung 
cancer diagnosis do not result in false positives. These tests could therefore be used 
as a second-line confirmatory test, following a prior test with high sensitivity but low 
specificity. It should be noted that the sample sizes for Clearbridge and ScreenCell 
datasets were small: 36 and 51 samples respectively. As such, the estimates of 
sensitivity and specificity values for these test datasets lack precision, as 
demonstrated by the wide 95% confidence intervals of these values. In order to 
make more precise estimates of the sensitivity and specificity of these tests in 
detecting cancer, a much larger sample size is required.  
Size-exclusion CTC isolation platforms like Clearbridge CTChip and ScreenCell Cyto 
have the benefit of being antibody-indedependent. CellSearch by Veridex is the most 
commonly used and the only FDA approved CTC isolation system in the market, 
which pulls EpCAM-positive CTCs from peripheral blood using microbeads coated 
with EpCAM antibodies. Compared to CellSearch, size-exclusion platforms like the 
Clearbridge CTChip and ScreenCell Cyto have the potential to isolate a much larger 
subset of CTCs compared to marker-dependent CTC isolation. CTCs have been shown 
to be very heterogeneous, ranging from having mostly epithelial characteristics to 
exhibiting mostly mesenchymal characteristics or falling some where within the 
spectrum.114 While EpCAM was chosen as a target CTC marker as it is highly 
expressed in a large number of epithelial carcinomas, a significant decrease (to one 
tenth) in CTC expression has been shown in CTCs compared to that in solid 
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carcinoma tissues.115 Despite less than ideal test sensitivities, there is therefore 
merit in pursuing research into size-exclusion CTC isolation platforms to avoid 
reliance on epithelial cell-specific markers.  
An ideal CTC-based test would allow for a number of different analyses aside from 
just CTC detection, most importantly CTC enumeration and molecular analysis. 
Studies have shown that a high CTC count is a marker of poor prognosis in lung 
cancer.71,73 These studies were conducted using the CellSearch CTC test kit, which 
isolates EpCAM-positive CTCs using antibody-coated microbeads. The Clearbridge 
CTChip, although EpCAM-independent and capable of isolating a larger fraction of 
the CTC population, subjects the cells to very high pressures, due to the microfluidic 
environment within the chip. This could lead to deformation and loss of CTCs due to 
shear stress, making enumeration data less reliable. The new CTChip FR, 
Clearbridge’s   latest   version   of   its  microfluidic   chip,   utilizes   a   spiral   path   for   blood  
flow through the chip, reducing the shear stress experienced by cells during 
filtration.116 The ScreenCell Cyto system allows for better preservation of the 
morphology of isolated cells and would be a better system for enumeration of 
trapped CTCs. The current lack of a single, widely-used system for CTC isolation and 
enumeration also makes comparison of enumeration data from different studies 
difficult, due to the different conditions and isolation parameters used in different 
CTC enumeration systems and techniques. Currently, CellSearch remains the most 
widely used CTC isolation and enumeration platform in published literature.  
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CTCs are an attractive target for study as they require less invasive methods for 
retrieval, can act as a surrogate for tumour tissue and are perfect models to study 
metastasis. An ideal CTC isolation system would also allow for further molecular 
analysis both for clinical diagnostic and laboratory research purposes. Molecular 
characterization of CTCs, for example, in their expression of specific lung cancer 
markers (e.g. CKs, TTF-1 and P63) and analysis of their mutational status (e.g. EGFR 
and EML-4-ALK) would be very useful for lung cancer diagnosis and subtype 
classification. Studying the different subpopulations of CTCs could help to identify 
the specific subpopulations responsible for metastasis and form the basis for future 
advanced lung cancer treatments.  
Due to the microfluidic nature of the Clearbridge CTChip, immunostaining of CTCs 
for lung cancer molecular markers (e.g. CKs, TTF-1 or P63) is difficult to perform 
within the chip. The high-pressure environment within the microchip is very 
sensitive, especially to solutions containing coloured pigments. During the early 
optimisation stages of haematoxylin and eosin staining within the chip, precipitation 
of the stains within the chip was a big problem, which took a lot of experimentation 
with different concentrations of stains and types of fixatives in order to overcome 
the problem. Similar problems occurred when immunostaining CTC cells in the 
CTChip, and required further optimisation before use. Unfortunately, the alternative 
approach, retrieving the trapped cells within the chip for analysis outside of the chip, 
proved unsuccessful, as trapped cells could not be retrieved from the chip without 
significant loss of cells (100%). The new Clearbridge CTChip FR, however, allows for 
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retrieval of trapped CTCs from the microchip for downstream analysis, and would be 
a better system to investigate in the future.  
The ScreenCell Cyto is more compatible with immunostaining, due to the greater 
accessibility of the cells trapped on the surface of the membrane filter. However, the 
membrane becomes degraded and occluded at high heat, preventing the cells from 
undergoing heat-induced epitope retrieval should it be necessary prior to staining. 
Further work would include experimenting with different conditions and protocols 
(e.g. using enzymatic instead of heat-based epitope retrieval) to allow 
immunostaining and mutation testing of CTCs trapped on ScreenCell Cyto filters. It 
would also be worthwhile to culture the isolated CTCs, to expand the population of 
cells available in order to characterise them, as little is known regarding the biology 
of CTCs. My initial attempts at this with commonly used cell culture medium and in 
vitro techniques did not prove successful, and optimisation of the culture conditions 
will be required to move forward in this area.  
CTCs are an attractive target for use in a non-invasive, liquid biopsy for cancer 
detection due to the relative ease of sample collection and isolation from peripheral 
blood. It is, however, not the only blood-borne target of interest in cancer 
diagnostics. Circulating, free, tumour-derived DNA (ctDNA) is another such target of 
interest in blood-based cancer detection. The presence of circulating, cell-free DNA 
(cfDNA) in blood serum is not a new discovery and was first described in 1977.117 
cfDNA is released to circulate in the peripheral blood during cell necrosis or 
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apoptosis, and ctDNA is a subset of circulating cfDNA originating from tumour cells. 
cfDNA can range from small 70bp to 200bp fragments to large 2kb fragments.  
Of note, total blood plasma cfDNA levels have been shown to be elevated in cancer 
patients compared to healthy subjects.118-120 Studies across cancer types have shown 
that cancer patients have an average cfDNA concentration of 180ng/ml of blood, 
ranging from 0 to more than 1000ng/ml, compared to healthy subjects, who have an 
average cfDNA concentration of 30ng/ml of blood, ranging between 0 and 
100ng/ml.121 cfDNA in post-op cancer patients with localized disease has been 
shown to decrease to levels in normal subjects and it has also been suggested that 
persistently high post-op cfDNA levels could correspond to the presence of residual 
disease.122,123 This indicates a correlation between cfDNA levels, and presumably 
ctDNA levels, and tumour burden.  
ctDNA cannot presently be isolated from cfDNA; ctDNA is only indicated by the 
detection of tumour-specific mutations in the total pool of cfDNA. Examples of types 
of tumour-specific mutations that are commonly detected are: various mutations in 
tumour-specific genes, loss of heterozygosity in tumour suppressor genes and 
epigenetic changes, e.g. demethylation of tumour oncogenes and hypermethylation 
of tumour suppressor genes.121  
Detection of a number of tumour-specific gene mutations in cfDNA has been 
reported in lung cancer. A study of 273 late stage NSCLC patients detected KRAS 
mutations in 11% of tumour tissues and 12.8% of matched cfDNA samples, with a 
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76.7% concordance. Tumours with KRAS mutations are known to have resistance 
against EGFR-TKI therapy. The same study showed a 5.3% response rate to EGFR-TKI 
treatment in patients with KRAS mutations in their cfDNA compared to a 29.7% 
response rate in patients with wild type KRAS in their cfDNA, suggesting a predictive 
prognostic value of cfDNA mutation testing in EGFR-TKI therapy in NSCLC.124 A 
separate study, investigating EGFR mutations in cfDNA from plasma and pleural 
effusions of late stage NSCLC patients also produced similar results. EGFR-TKIs have 
been shown to be more effective in treating EGFR mutant tumours compared to wild 
type tumours, and similarly, this study showed higher response rate in patients with 
mutant EGFR detected in their cfDNA compared to wild type EGFR, as well as longer 
progression-free and overall survival.125  
In addition to detecting tumour-specific gene mutations in cfDNA, studies have also 
been done to investigate epigenetic alterations in cfDNA of cancer patients. One 
study investigated methylation-dependent mechanisms of transcriptional silencing in 
cfDNA from patients with advanced stage lung cancer across histological subtypes. 
Tumours with hypermethylation of the G2 cell cycle control gene 14-3-3-σ  have  been  
shown to experience greater response rates when treated with cisplatin-based 
chemotherapy. This study found that patients with methylated 14-3-3-σ   in their 
cfDNA experienced significantly longer survival rates compared to those with 
unmethylated 14-3-3-σ   in   their   cfDNA,   and   they   suggest   that   evaluation   of  
methylation status in cfDNA is convenient and reliable enough to replace evaluation 
of gene methylation status from tumour tissue.126  
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ctDNA is an attractive target for use as a liquid biopsy due to a variety of factors, the 
most apparent being the relative ease of isolating cfDNA compared to CTCs. As 
mentioned previously, there are a variety of different systems for isolating CTCs, 
each with its own pros and cons, but they often require specialised instruments, 
whether at the isolation stage or detection stage. Isolation of ctDNA is more 
straightforward and easier to achieve using standard plasma DNA preparation 
protocols. Mutation testing can then conducted using a variety of widely-used and 
well-established processes, for example, next-generation sequencing and 
comparative genomic hybridization. ctDNA isolation also does not depend on the use 
of molecular markers, as compared to some CTC isolation systems (e.g. CellSearch). 
This means that ctDNA data presents an overall picture of the tumour genome, 
whereas CTC analyses often offer data on individual clonal cells. Due to the relative 
ease of processing, ctDNA is becoming an increasingly attractive biomarker for use in 
clinical settings, e.g. as a target for liquid biopsy, but there are benefits to the use of 
both CTCs and ctDNA in the research setting, depending on the intended outcome of 
a particular investigation.  
Recently, research groups are taking a more holistic approach to studying these 
circulating blood-borne markers. One such group in the UK, headed by Professor 
Charles Swanton,   is   interested   in   “TRAcking   non-small cell lung Cancer Evolution 
through   therapy   (Rx)”.   This   multi-center Lung TRACERx study aims to relate 
intratumour heterogeneity, both genetic and functional, to patient treatment and 
survival outcomes in lung cancer. Importantly, both CTC and cfDNA analyses feature 
prominently in the blood-based aspects of the study design, in order to give the 
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most comprehensive data possible when put together with other tissue-based 
analyses.127 
Improving the quality of CTC and ctDNA research requires the development of better 
isolation and characterisation methodologies, as well as the validation of these 
methodologies for reliability and robustness, for use in a routine clinical setting. 
CANCER-ID is a European consortium comprising academic and clinical researchers, 
small-to-medium sized enterprises and pharmaceutical companies, with the aim of 
assessing and improving the clinical utility of blood-based biomarkers such as CTCs 
and cfDNA in liquid biopsies. To bring the idea of a liquid biopsy closer to clinical 
relevance, they aim to combine expertise in the development of novel methods for 
CTC and cfDNA isolation and characterization with assay validation and 
improvements in assay robustness. Patients with NSCLC make up one of the two 
cohorts of subjects in this study. Briefly, the group aims to compare various methods 
for CTC enumeration and isolation, cfDNA analysis and also conduct clinical 
validation of these different studies compared to tissue biopsies.128  
The second part of my thesis investigated EpCAM cleavage in lung cancer, to 
determine whether the mechanisms of cleavage previously reported for other types 
of cancer also occurred in lung tumours. My immunoblotting experiments using both 
lung tissue and cell lines, consistently detected two bands of different molecular 
weights when probed with EpCAM antibodies; a 42kDa band corresponding to full-
length EpCAM and a 37kDa band corresponding to cleaved EpCAM. Initially, I 
hypothesized that the 37kDa fragment corresponded to EpCAM that had undergone 
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EpICD cleavage. However, subsequent experiments showed that this 37kDa band 
contained both EpICD and EpEX domains. After confirming that the difference 
between the 42kDa and 37kDa bands was not due to differential glycosylation, I 
hypothesized that full-length EpCAM was being cleaved at an N-terminal site. The 
37kDa band therefore corresponded to two distinct subpopulations of cleaved 
EpCAM: EpCAM without EpICD and EpCAM without EpN. This was a novel discovery 
at the time, but since then, a study in 2013 has reported N-terminal cleavage of 
EpCAM in EpCAM-transfected human embryonic kidney cells, as well as in cell lines 
of colon carcinoma (HT29 and CaCo2), epidermoid carcinoma (A431) and hepatoma 
(HepG2).109  
EpN cleavage has implications for a number of EpCAM-targeted therapies currently 
in development. The EpCAM antibodies currently being tested function by binding to 
cancer cells, resulting in antibody-dependent cellular cytotoxicity and complement-
dependent cytotoxicity. Two EpCAM antibodies, catumaxomab and MT110, are 
currently being tested in the clinic for treatment of lung cancer. Catumaxomab is a 
bi-specific antibody, with an EpCAM-binding arm to target cancer cells and a CD3-
binding arm to target T-cells, to improve removal of tumour cells by peripheral blood 
mononuclear cells.129 However, the EpCAM-binding arm of catumaxomab is specific 
to an area within EpN. The loss of EpN from full-length EpCAM, demonstrated in my 
experiments  in  lung  cancer  cells,  would  significantly  reduce  catumaxomab’s  ability  to  
target these cancer cells for eradication. MT110, another bi-specific EpCAM-antibody 
therapy in development also recognises the N-terminal region of EpCAM, and would 
likewise suffer from the same limitations when used to treat EpN cleaved lung 
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cancer cells.130 It would be relatively straightforward to test if catumaxomab and 
MT110 can bind to EpCAM expressing cells that have undergone EpN cleavage, to 
test this hypothesis. 
This study is the first to demonstrate that EpN cleavage occurs in a TACE-dependent 
manner in lung cancer cells, and also corroborates studies that show EpICD-cleavage 
occurring in a PS-2-dependent manner, previously only demonstrated in breast and 
colon cancers.96,97 What this study did not determine was the exact sequence of 
EpCAM cleavage that occurs in lung cancer. Studies using breast and colon cancer 
cell lines suggest that EpEX cleavage occurs first and is necessary before cleavage of 
EpICD.96 However, the results in this study do not support this theory, and EpICD 
cleavage was detected without EpEX cleavage in immunoblotting experiments. The 
discovery of EpN cleavage adds an additional layer of complexity to this process. 
Future work would be needed to investigate if each cleavage event occurs 
independently from the other, or if one cleavage event stimulates another.   
This study was also hampered by the inability to directly detect free intracellular 
EpICD via immunoblotting. This is likely due to the very small size of free EpICD, of 
approximately 3kDa. Instead, EpICD cleavage was inferred by the loss of EpICD from 
full-length or EpN-cleaved EpCAM. Experimentally, an immunoblot band detected by 
EpEX antibodies but not EpICD antibodies would have been inferred to have 
undergone EpICD cleavage. In order to overcome this problem and to directly detect 
free intracellular EpICD, I planned to stably transfect an A549 cell line to express 
EpCAM with a GFP tag attached to its EpICD domain). This EpCAM-GFP fusion 
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construct would result in the release of EpICD-GFP upon cleavage from full-length 
EpCAM. The addition of a GFP tag (with a molecular weight of approximately 27kDa) 
would increase the overall molecular weight of EpICD in order to increase the 
chances for direct detection via immunoblotting. Although increasing the size of 
EpICD could alter its intracellular behaviour, it would be useful for direct detection of 
EpICD cleavage.  
Another important aspect of EpCAM research for future study would be the effect of 
EpCAM cleavage on cancer progression. The effect of the different EpCAM cleavage 
events on cell proliferation and cell migration could be studied. My work in creating 
a stably EpCAM-GFP-transfected A549 cell line for all the purposes outlined above is 
ongoing, but not yet achieved due to time constraints. At this stage, the EpCAM-GFP 
plasmid and control vectors have been purchased, cloned into E. coli., expanded in 
culture, purified via plasmid miniprep and verified via restriction enzyme digestion. 
An A549 cytotoxicity profile to determine the optimum antibiotic selection 
concentration prior to transfection was started but not completed in time for 
inclusion in this thesis (see appendix, sections 7.1 and 7.2). 
Additionally, immunohistological staining of a larger sample size of tumour sections 
would be required to see if the patterns of expression described in this study are 
representative. Further molecular characterization of cancer cell subtypes in these 
sections, for example with epithelial or mesenchymal markers, would also be useful 
in determining whether differences in EpCAM cleavage and sub-cellular localisation 
could be due to EMT events. This would provide a good reference and comparison 
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for in vitro studies of the effect of EpCAM cleavage on proliferation, migration and 
invasiveness of cancer cells discussed previously. 
In conclusion, the first half of this study has shown the potential for antibody-
independent size-dependent isolation of circulating tumour cells for use in the 
diagnosis of lung cancer. In addition to diagnostics, EpCAM-independent CTC 
isolation is important in order to isolate a more representative population of total 
CTCs, which can then be investigated to better understand the process of metastasis 
and to provide new targets for lung cancer therapy. The importance of this is 
underscored by the results of the second half of this study, which demonstrated that 
EpCAM cleavage occurs in lung cancer cells, via a more complex process than 
originally expected. Progress in either field of EPCAM-independent CTC isolation or 
EpCAM cleavage would have a direct impact on the other. 
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7 APPENDICES  
 
7.1 Ongoing work 
In order to increase the size of EpICD to enable detection in immunoblots, I wanted 
to transfect a low or non-EpCAM expressing lung cancer cell line with a plasmid 
containing an EpCAM C-terminal-fusion protein construct. I have started work on 
transfecting the low EpCAM-expressing lung adenocarcinoma cell line A549 with an 
plasmid containing an EpCAM-GFP construct, but did not manage to complete this 
work in time for inclusion in this thesis. I have described the processes that I have 
carried out below. 
7.2 Materials and methods 
7.2.1 Plasmids and bacterial cell lines  
The EpCAM-GFP (C-terminal tagged) plasmid clone (#RG201989) and empty control 
vector pCMV6-AC-GFP (#PS100010) were purchased from Origene. One Shot TOP10 
Chemically Competent E. Coli was purchased from Invitrogen (#C4040-10). A549 cells 
were obtained from lab stocks. 
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7.2.2 Transformation of competent E. coli cells with EpCAM-GFP and vector 
plasmids  
A vial of E. coli cells was thawed on ice. 2Pl of EpCAM-GFP plasmid was added into 
the cells, mixed gently and incubated on ice for 30 minutes. Mixture was transferred 
to a 42qC water bath for 30 seconds, then incubated on ice for 2 minutes. 250Pl of 
S.O.C. medium was added to the mixture and incubated at 37qC on a shaking 
incubator. After 1 hour, 20Pl of the mixture was streaked onto ampicillin-agar plates 
(50Pg/ml). Plates were incubated upside down at 37qC overnight. The process is 
repeated concurrently, using the pCMV6-AC-GFP empty vector control.  
7.2.3 Colony selection and culture  
The following day, distinct colonies were picked using 20Pl pipette tips, and 
inoculated into 5ml of LB/ampicillin culture medium (50Pg/ml) in a 50ml falcon tube. 
2 colonies were picked per EpCAM-GFP- or empty pCMV6-AC-GFP vector-
transformed cells. Cells were incubated in a shaking incubator at 37qC. After 6 hours, 
100Pl of culture was inoculated into 30ml of fresh LB/ampicillin culture medium in 
50ml falcon tubes and incubated in a shaking incubator at 37qC overnight. 
7.2.4 Plasmid purification 
The following day, the tubes were centrifuged at 5000g to pellet the bacterial cells. 
The supernatant was discarded and plasmids were purified using the QIAprep Spin 
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Miniprep   Kit,   according   to   the  manufacturer’s   protocol.   Plasmids  were   stored   at   -
20°C until needed. 
7.2.5 Plasmid digest and agarose gel electrophoresis 
1Pg of plasmid was incubated with 10X buffer C, 100X BSA and made up to 19Pl with 
distilled water. 0.5Pl of SgfI and XhoI restriction enzymes were added to the mixture 
and left to digest at 37°C for 2 hours. After digestion, 5Pl of the plasmid digest mix 
was added to 1Pl of 6X DNA loading dye and loaded onto a 1.5% agarose/TBE gel 
containing Gel Red. A voltage of 120V was applied across the gel for 20 minutes and 
bands were visualized under UV light. 
7.2.6 Geneticin resistance titration  
The EpCAM-GFP and pCMV6-AC-GFP control plasmids contain a neo gene, which 
confers resistance to geneticin (G418). In order to determine the optimum 
concentration of geneticin for antibiotic selection, a cytotoxicity profile of A549 at 
varying geneticin concentrations was carried out. A549 cells were seeded in each of 
60 wells of a 96 well plate at 5000 cells per well in complete RPMI medium, and 
incubated overnight at 37°C and 5% CO2. The next day, each well was about 60-80% 
confluent. The culture medium was discarded from each well, and replaced with 
fresh complete medium containing increasing concentrations of geneticin.  Table 5-1 
shows the set-up of the plate. Culture medium was replaced with fresh complete 
medium with geneticin every 2 days. After 7 days, wells were observed for cell 
death. 
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Table 7-1. Layout of geneticin toxicity profile plate 
 
(Pg/ml) 1 2 3 4 5 6 7 8 9 10 11 12 
A  0 100 200 300 400 500 600 700 800 900 1000 
B  0 100 200 300 400 500 600 700 800 900 1000 
C  0 100 200 300 400 500 600 700 800 900 1000 
D             
E   1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 
F   1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 
G   1100 1200 1300 1400 1500 1600 1700 1800 1900 2000 
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[Reproduced with permission from Wolters Kluwer Health.]
 181 
 182 
 183 
 
 
[Reproduced with permission from Elsevier.]
 184 
 185 
 186 
 187 
 
[Reproduced with permission from Elsevier.] 
 188 
7.4 Posters 134 
 
[Reproduced with permission from Elsevier.] 
 189 
7.5 Patent 
 
 190 
 
 191 
 192 
 193 
 
